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I. Introduction 
 
 
Cancer is a major health problem worldwide, its occurrence is increasing because of risk 
factors such as smoking, overweight, physical inactivity, growth and aging of the 
population and changing reproductive patterns associated with urbanization and economic 
development. In 2012, 14.1 million new cancer cases and 8.2 million deaths occurred 
worldwide [1]. All in all, the most common cancers occurring per year, are lung (1.82 
million), breast (1.67 million) and colorectal cancer (1.36 million) while the most 
common causes of death were lung cancer (1.6 million), liver cancer (745.000) and 
stomach cancer (723.000). According to estimates, over 20 million new cancer cases are 
expected annually as early as 2025 [2]. Among females breast cancer is the most 
frequently diagnosed type of cancer while lung cancer is the leading type diagnosed in 
males. By trend, people in developing countries display a lower survival rate than people 
in developed countries because of a combination of late stage diagnosis and limited 
access to timely and standard treatment. The application of existing cancer control 
knowledge, implementing programs for tobacco control, vaccination (e.g. for liver and 
cervical cancers), early detection and treatment, as well as public health campaigns 
promoting an active and healthy lifestyle contribute to the fight against cancer [3]. The 
classical therapeutic strategies are surgery, radiotherapy and chemotherapy. Especially 
chemotherapy is affiliated with a variety of wearing side effects because the used drugs 
do not specifically affect cancer cells, but all cells with a fast division rate, e.g. cells of 
the skin, the mucosa and the blood and hair roots. This is the reason why patients suffer 
from, among other side effects, skin problems, gastrointestinal pain and hair loss. The 
solution for such problems is that cancer therapy has to become more target-oriented.  
The term cancer itself is used for a large group of diseases that are able to batter almost 
any part of the body. One decisive characteristic is an uncontrolled cell division and so 
the rapid creation of abnormal cells that grow beyond their usual boundaries [4]. 
Normally, the body forms as many cells as needed because old and damaged cells die and 
have to be replaced by new ones. In cancer processes, this regular mechanism does not 
work properly, so old or damaged cells are able to survive and unneeded new cells are 
produced. The initiation of cancer is marked by a carcinogenic influence on a normal cell, 
it is due to either environmental factors such as tobacco, obesity, infections, radiation or it 
is due to inherited genetics [5]. The genetic changes that contribute to cancer tend to 
affect three main types of genes, namely proto-oncogenes, tumor suppressor genes, and 
DNA repair genes [6]. Many cancers are represented through solid tumors while others, 
e.g. blood cancer as leukemia, do not form a solid growth. Cancerous tumors are 
malignant, which means they can spread into or invade nearby tissues. Some of the cells 
of the growing tumor also use the blood or lymph system to reach parts of the body, 
distant to the original tumor, and form new tumors there. This is a characteristic benign 
tumors normally do not show. The difference between cancer cells and normal cells is the 
less specialisation of tumor cells, they do not mature into very distinct cell types with 
clear functions, so they are able to divide without stopping. In addition, cancer cells are 
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able to ignore signals that normally tell cells to stop dividing or to begin a process known 
as programmed cell death or apoptosis, which the body uses to get rid of unneeded cells 
[6]. According to recent publications, tumor initiating cells, so-called cancer stem cells 
(CSCs), possibly play an important role in tumor formation. They constitute a small 
minority of neoplastic cells within a tumor, have strong self-renewing properties and are 
defined by their ability to seed new tumors, which is why they are called tumor initiating 
cells [7]. They are associated with the formation of metastases and promotion of 
resistances against anti-cancer therapy [8]. In addition to this, there exists a mechanism 
called epithelial-mesenchymal transition (EMT) which is a highly conserved cellular 
process that transforms epithelial cells into mesenchymal cells. EMT is involved in 
normal embryogenesis and tissue repair, but it also contributes to tumor progression, 
including tumor metastasis, therapy resistance and disease recurrence. The link between 
EMT and CSCs might be the relevance of an EMT for the acquisition and maintenance of 
stem cell-like characteristics [9].  
In 2000, Hanahan and Weinberg defined six hallmarks of cancer, including sustained 
proliferative signaling, evading growth suppressors, resistance against cell death, enabling 
replicative immortality, inducing angiogenesis and activating invasion and metastasis. 
These biological capabilities are acquired during cancer development and form the 
perfect strategies to outlast all efforts of the body to fight cancer and to create the best 
environment for development [10]. In 2011, these scientists enlarged their list of 
hallmarks with the deregulation of cellular energetics, the avoidance of immune 
destruction, tumor promoting inflammation and genome instability and mutation as 
additional capabilities of cancer for its development. In Figure 1, an overview on these 
hallmarks is illustrated [11].  
Cancer is right now and also will be in the coming years one of the major burdens on 
human and animal health. Veterinary oncology is actually mainly focussing on 
companion animals such as cats and dogs which suffer from many of the same types of 
cancer like humans do and are often treated with the same drugs [12]. But animals 
themselves have been widely used to develop and test anti-cancer therapeutics. For the 
main part of them rodents were taken which represent a widely used model in the fight 
against cancer. They represent a proper model because their anatomy, physiology and 
genetics are well-understood. Their genetic, biological and behavior characteristics are 
similar to those of humans. Rodents are relatively easy to handle, they adapt to new 
conditions very fast, they reproduce very quickly and have a short lifespan (two to three 
years), so several generations of mice can be observed in a relatively short period of time. 
Among laboratory mice, a greater variety of different strains with or without deficiencies 
compared to all other animals is existing, additionally there is the possibility to create 
knock-out or knock-in mouse models which are increasingly established in cancer 
research. This offers the possibility to choose the most adequate mouse model for a tumor 
experiment [13]. In vivo models are one of the most important steps during the long 
process of drug development for cancer therapy, they constitute the transition of pure in 
vitro results to real therapeutic use. 
This thesis focuses exclusively on the establishment of murine tumor models to evaluate 
new promising anti-cancer approaches, the use of natural and synthetic compounds as 
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chemotherapeutics in cancer therapy, partly in regard to the influence of an inhibition of 
cyclin dependent kinase 5 (Cdk5) as a target. Our lab concentrates on a variety of in vitro 
projects to evaluate the anti-cancer properties of different experimental compounds. The 
establishments of corresponding animal experiments to substantiate these in vitro data 
and to generate profound knowledge on the efficacy of these compounds in vivo are the 
content of this thesis. 
 
Figure 1: Hallmarks of cancer according to Weinberg et al. [11] [10] 
 
 
1. Investigated experimental anti-cancer drugs 
 
Our lab works with a variety of compounds, either natural ones (DFG, FOR 1406) or 
synthetic ones, in order to evaluate their anti-cancer properties. In this thesis, mouse 
models were used for a variety of in vivo experiments with both types of these 
experimental drugs. 
 
 
1.1. Natural compounds 
 
A natural product is defined as a compound or substance produced by a living organism. 
They can possess pharmacological or biological activity which makes them useful for 
drug development [14]. Nature itself has been a source of medicinal products for 
millennia, in this context animals, plants, microorganisms and organisms from the sea 
play important roles as sources [15]. Natural products have always been the origin of 
many ingredients in medicine, even more than 80% of drug substances were natural 
products themselves or were inspired by a natural compound [16]. The amount of drugs 
of natural origin in development is immense. At the end of 2013, more than 100 natural 
products and natural product derived compounds were arranged in clinical trials or in 
registration processes. The area of indications ranges from oncology, anti-infectives, 
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cardiovascular and metabolic diseases to inflammatory and neuronal illness [17]. In the 
field of anti-cancer and anti-infective agents even two-thirds of all drugs are derived from 
natural products. Hence, such drugs continue to make great contributions to human and 
animal health [18]. One of their key features is their enormous structural and chemical 
diversity. Their frequent use in therapy, the huge number of diseases which are treated or 
prevented by them and the rate of wide structural diversity, including their application as 
templates for semi-synthetic and total synthetic modification speak for the importance of 
natural compounds in modern medicine [14]. Prominent representatives are e.g. paclitaxel 
which was isolated from the bark of a yew tree in 1967 and is now clinically approved 
and widely used to treat breast and ovarian cancer [19] and bendamustine, a nitrogen 
mustard, which is approved for the treatment of chronic lymphocytic leukemia (CLL) and 
lymphomas [20]. Natural compounds mostly show their effective properties, the basic 
challenge is to evaluate the mechanism behind them. However, synthetic drugs are 
designed to work according a specific mode of action and their effectiveness has to be 
proven.  
The focus of this thesis is the establishment of in vivo models for the evaluation of natural 
compounds as chemotherapeutics. The effects of several substances will be evaluated 
concerning their effects on tumor development, growth and dissemination.  
In the following sections the natural substances used in this thesis will be described in 
more detail. 
 
 
1.1.1. Archazolid A 
 
Archazolids A and B were first isolated from cultivated myxobacteria Archangium 
gephyra and its related genus Cystobacter violaceus, they consist of a macrocyclic 
lactone ring with a thiazole side chain [21]. Next to argyrins [22], tubulysin [23] and 
gephyronic acids [24], they are the fourth compound which was isolated from these 
specific myxobacteria. The mode of action of archazolids is based on their inhibitory 
effect on the V-ATPase activity of cells [21]. 
Vacuolar (H+)–ATPases (V-ATPases) are proton pumps which are ubiquitously 
expressed on various membranes, including lysosomes, endosomes, vesicles and the 
plasma membrane. They depend on adenosine triphosphate (ATP) and play a crucial role 
in endo- and exocytotic processes of the cell [25] [26]. They regulate pH homeostasis in 
endomembrane systems by translocating protons across the plasma membrane. In cancer 
tissues, this proton pump is overexpressed within the plasma membrane [27], the 
extrusion of protons via V-ATPase causes extracellular acidification and contributes to 
the maintenance of an aberrant pH gradient between the alkaline cytosol and the acidic 
extracellular environment. The low pH of tumor extracellular microenvironment may 
induce the increased secretion and activation of proteases. In fact, the promoting effect of 
V-ATPases on cancer invasion and metastasis mainly relies on their ability to maintain an 
acidic pH of extracellular microenvironment [28]. This enables tumor cells to be invasive 
and to migrate into other tissues [29]. 
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V-ATPases are consisting of the V0 complex which is membrane bound and responsible 
for the translocation of protons and the catalytic V1 complex which is oriented towards 
the cytosol [30]. Archazolid binds to the subunit c of V0 which forms an H+ binding rotor 
ring that transports protons from the cytoplasm to the endosomal/lysosomal lumen or the 
extracellular space. It was already shown that archazolid A reduces tumor cell 
proliferation and migration through the inhibition of V-ATPase in vitro and in vivo [31]. 
This has to be the initial point for further in vivo investigations to enlarge the spectrum 
where archazolid can be used. 
 
Figure 2: Chemical structure of archazolids [21] Archazolid A: R = CH3,  Archazolid B: R = H 
 
 
1.1.2. Tetrandrine 
 
Tetrandrine was originally isolated from the root of creeper Stephania tetrandra, a 
Chinese herb which has been used in oriental medicine for several decades [32] [33]. It is 
an alkaloid with a variety of pharmacological activities such as immunomodulating, anti-
hepatofibrogenic, anti-inflammatory, anti-arrhythmic, anti-portal hypertension, 
neuroprotective and anti-cancer activities [34] [35] [36]. Depending on the cell line, 
tetrandrine induces cell cycle arrest in different phases and it also induces apoptosis in a 
variety of cancer cells [34]. It has received considerable attention during the past decade 
owing to its interesting pharmacological property as a Ca
2+
 antagonist, especially with its 
action as an L-type Ca
2+
 channel inhibitor [37]. It also interacts with non-voltage 
dependent Ca
2+
 channels in blood vessels, based on contractility experiments [38]. In 
recent studies it was shown that tetrandrine is a potent inhibitor of nicotinic acid adenine 
dinucleotide phosphate (NAADP)-stimulated calcium release. NAADP is a highly potent 
intracellular calcium-mobilizing agent which makes intracellular calcium channels to 
release Ca
2+ 
from endosomes and lysosomes. So-called two-pore channels (TPCs), which 
belong to the family of voltage-gated ion-channels, are the major calcium channels 
activated by NAADP, and tetrandrine was found to be a very potent agent to block TPC1 
and TPC2 [39] [40].  It was also shown that tetrandrine has potency as a multidrug 
resistance modulator by using it as anti-cancer drug in combination with other anti-cancer 
agents [41]. Based on already performed in vivo experiments with tetrandrine [42] where 
it showed clear anti-cancer effects, we established a murine tumor dissemination model to 
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investigate the function of TPC1 and TPC2 in cancer processes, tetrandrine was used as a 
tool within these experiments. 
 
Figure 3: Chemical structure of tetrandrine [33] 
 
 
1.1.3. Soraphen A 
 
Originally, soraphen A was isolated from the culture broth of soil-dwelling 
myxobacterium Sorangium cellulosum [43]. The first focus of this polyketide natural 
product lay on its anti-fungal activity [44]. During recent years, this focus concerning use 
and effectiveness of soraphen A switched to its ability to also inhibit acetyl Coenzyme A 
carboxylase (ACC) activity in other beings than fungi [45]. ACCs are responsible for the 
adenosine triphosphate (ATP) dependent catalyzation to transform acetyl-CoA to 
malonyl-CoA, which is the first step of fatty acid biosynthesis and it is responsible for the 
speed rate of the mechanism. Two major domains are part of this enzyme, first the biotin 
carboxylase domain (BC) and second, the carboxytransferase domain (CT), both are 
connected through the biotin carboxyl carrier protein (BCCP) [46]. ACC has two 
isoforms, ACC1 is present in lipogenic tissues (liver, adipocytes) and ACC2 exists in 
oxidative tissues (liver, heart, skeletal muscle), both share on overall amino acid identity 
of 75% [47]. When one or both ACC isoforms are inhibited, the amount of intracellular 
malonyl-CoA lowers which causes an increase in the rate of fatty acid oxidation and it 
lowers the rate of fatty acid synthesis in cells [46]. Different ACC inhibitors have already 
shown promising results concerning treatment of insulin resistance and obesity. Soraphen 
A itself inhibits fungal and other eukaryotic ACC systems as well as mammalian ACCs 
[48]. It binds to the biotin carboxylase domain dimer and disrupts the oligomerization of 
ACC and inhibits its activity [49]. So, soraphen A has the potency to be used for 
treatment of obesity, diabetes and cancer [50]. It was shown that development and 
progression of cancer depends on the expression and activity of proteins which are 
involved in the fatty acid synthesis. The addition of soraphen A to cancer cells, even in 
nanomolar concentrations, blocks the fatty acid synthesis and stimulates their oxidation 
which leads to the situation that cancer cells lack phospholipids, they stop their 
proliferation and apoptosis starts because cancer cells depend on ACC activity to 
guarantee their sufficient supply [49]. We evaluated the in vivo effect of soraphen A 
concerning tumor growth and dissemination in different murine models. 
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Figure 4: Chemical structure of soraphen A [43] 
 
 
1.2. Synthetic compounds 
 
Chemical synthesis is a tool which has been successfully used for many decades to 
produce and establish a variety of compounds, many of them are in clinical use now. 
Chemical synthesis is the preparation of a compound by performing various chemical 
reactions, it can also be used to prove the chemical structure of a compound or to improve 
its properties [51] [52] [53]. Traditionally, synthetic chemistry in drug discovery has been 
a main source of new structural classes. Since analogy plays an important role in applied 
research, it is not surprising that it became a crucial strategy in medicinal chemistry [54]. 
Compounds are also synthesized to test a chemical theory, to create a new or better 
chemical, or to confirm the structure of a material isolated from a natural source. 
Chemical synthesis can also be used to supplement the supply of a drug that is commonly 
isolated in small amounts from natural sources [51].  
In our lab we focus on the evaluation of natural and synthetic compounds for their use as 
novel chemotherapeutics in cancer therapy, the synthetic substances used in this thesis 
will be described in the following sections in more detail. 
 
 
1.2.1. PS89 
 
PS89 is a close analogue to T8 which was found during a screening of a commercial 
compound library on search of a chemosensitizer of etoposide-induced apoptosis in 
various cancer cell lines. PS89 is a completely new compound which was first described 
in 2014 [55]. Resistance against chemotherapeutic drugs is a serious problem in effective 
anti-cancer therapy. There are two categories of resistance, first the acquired one, which 
develops during the treatment with an initially sensitive drug because of adaption, 
mutation and usage of sub-pathways and second, the intrinsic one, in which the resistance 
is already present before start of the therapy which makes the treatment ineffective right 
from the beginning [56]. The consequence is that tumor cells do not succumb 
programmed cell death or apoptosis and that therapy fails [57]. The solution for this 
problem might be to dispose a combinatorial treatment or to use sensitizing compounds 
together with chemotherapeutic drugs. PS89 is one of those sensitizers. It inhibits the 
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protein disulfide isomerase (PDI) and triggers the chemosensitization of cancer cells [55]. 
PDIs are enzymes which catalyze the formation of disulfid bonds in the oxidative folding 
pathway which takes place in the endoplasmatic reticulum (ER) of eukaryotic cells [58]. 
It is organised in four thioredoxin-like domains (a b a`b`), the sites with the redox activity 
are the a- sides [59]. Cancer cells require an increased protein synthesis which results in 
imbalance between the load and capacity of protein folding and leads to a cellular 
condition known as ER stress. That is the trigger for a variety of processes to restore 
homeostasis, termed as unfolded protein response (UPR) [60]. This is mediated by so-
called chaperones, PDI is one of them. They maintain the ER homeostasis and support 
cancer cell survival, so they are a potential target to fight chemoresistance [55]. PDI 
family proteins were already demonstrated to be involved in a wide range of 
physiological and disease processes [61]. Here, we wanted to evaluate the effects of PS89 
in vivo for the first time. 
Figure 5: Chemical structure of PS89 [55] 
 
 
1.2.2. Roscovitine and its analogue LGR 2674 
 
Roscovitine (CYC-202, (R)-roscovitine, seliciclib) is a small molecule which inhibits 
cyclin-dependent kinases (Cdks) through direct competition at the ATP-binding site by 
interacting with the amino acids that line up the ATP binding pocket of the Cdk catalytic 
domain. It belongs to a family of purines which all share a basic ring structure. It inhibits 
Cdk1, Cdk2, Cdk5, Cdk7 and Cdk9 [62] [63]. Roscovitine is a close analogue to 
olomoucine which is one of the earliest potent and specific inhibitors of Cdks [64] [65]. 
But in comparison to the forerunner olomoucine, roscovitine shows a 10-fold higher 
efficiency towards Cdk2 and a 20-fold higher efficiency towards Cdk5. A lot of human 
tumors are associated with an abnormal overexpression of Cdk proteins and their 
regulators which makes it indispensable to lay the focus on an active search for chemical 
Cdk inhibitors. Amongst them,  roscovitine is one of the most promising because it holds 
a great variety of effects on tumor cells [66] [64]. Roscovitine was shown to induce cell 
cycle arrest in the G2/M and G1/S phase [66] and leads to induction of apoptosis in many 
cancer cell lines at all phases of the cell cycle. It was also evaluated that roscovitine has 
synergistic effects with other anti-cancer agents. It also showed its potency in a variety of 
in vivo experiments [67]. So, it is widely inserted as a biological tool in cell cycle, cancer, 
apoptosis and neurobiology studies [63]. 
LGR 2674 is an analogue of roscovitine which has been synthesized by Dr. Vladimir 
Krystof (Palacky University, Czech Republic). Next to other analogues (EU Project 
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collaboration PROKINASE No. 503467), it is claimed to show a higher potency and 
selectivity in comparison to (R)-roscovitine. This is what we wanted to evaluate in our 
experiment. The differences concerning the original substance is that the purine scaffold 
has been changed to pyrazolo [4,3-d] pyrimidine and an alteration of the side chain at the 
position C5. 
Roscovitine was used as a Cdk5 inhibitor in combination with mice carrying an inducible 
endothelial Cdk5 knock-out to evaluate their effects on tumor growth while LGR 2674 
was chosen for a xenograft model concerning growth reduction of HCCs. 
 
Figure 6: Chemical structures of R-roscovitine (left) and LGR 2674 (right) [68] 
 
 
1.2.3. Dinaciclib 
 
Dinaciclib (SCH727965) is also a potent small molecule inhibitor of cyclin-dependent 
kinases (Cdks), it intensely affects Cdk1, 2, 5 and 9 [69]. It was developed during a 
screening for proper candidates which integrated efficacy and tolerability parameters to 
identify potential Cdk inhibitors with a suitable balance of activity and tolerability. The 
inhibition of Cdks in general is more and more used in cancer therapy. Flavopiridol and 
roscovitine are two clinically studied and common used Cdk inhibitors, which are also 
based on the pyrazolo–pyrimidine scaffold as dinaciclib is [70]. It was shown that 
dinaciclib detracted volume of established solid tumors in a variety of murine models 
with used dosages below the maximally tolerated level [71]. Dinaciclib is used in clinical 
trials for a range of solid-organ malignancies. Currently, it is undergoing clinical phase II 
trial in the treatment of non-small-cell lung cancer [72]. Compared with flavopiridol, it 
inhibits Cdk1 and Cdk9 with equal potency, but with 12-fold higher potency Cdk2 and 
14-fold higher potency Cdk5, in which we were interested in [71]. Dinaciclib binds to the 
ATP side of Cdks through a complex network of binding interactions [73] and it 
interferes in the unfolded protein response (UPR) whose dysregulation plays a role in 
cancer pathogenesis. This mechanism is based on Cdk1 and Cdk5 [74]. Dinaciclib was 
used in its function as an inhibitor of Cdk5 in the limiting dilution experiment with 4T1-
luc cells (murine breast cancer).  
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Figure 7: Chemical structure of dinaciclib [75]  
 
 
2. Compounds used for combinatorial treatment 
 
Next to the natural and synthesized compounds we were mainly interested in, some other 
drugs were used for combination in the in vivo experiments due to their mode of actions 
or their consisting establishment for certain indications. The intent of these combinations 
was to reach synergistic effects. 
Concerning the combinatorial use of drugs, additive, synergistic and antagonistic effects 
have to be differentiated. Additive effect means to get the sum of the effect from one drug 
plus the effect of the combinatorial drug while a synergistic combination leads to effects 
which are higher than the sum of the effects of the individual drugs [76]. An antagonistic 
effect would lead to an abolition of the effect of two drugs, so there is less or no outcome.  
The compounds which were just used for combinatorial treatment are illustrated in the 
following. 
 
 
2.1. Nutlin-3a 
 
Nutlin-3a is a small-molecule inhibitor of the interaction between tumor suppressor p53 
and its negative regulator mouse double minutes clone 2 (MDM2) [77]. In recent years, 
the disruption between MDM2 and p53 interaction turned out to be a promising 
therapeutic strategy [78]. Nutlins are cis-imidazoline analogues which were identified 
during screening of synthetic chemical libraries and then optimized for potency and 
selectivity. Nutlin-3a showed the highest effectivity [77] [79]. P53 is a very important 
protein concerning tumor suppression, its pathway is always disturbed in cancer cells 
either by inactivating mutations or by other mechanisms which lower the p53 level, e.g. 
MDM2 overexpression [80]. MDM2 itself shows an overexpression in a variety of tumors 
[81] and is associated with a high aggressiveness in cancer disease [82]. The nutlin 
strategy is to displace p53 from the binding pocket of MDM2 by docking on the N-
terminal of MDM2 [81], so the p53 level increases again and p53 is able to attend its 
functions [83]. Nutlin-3a already showed proper results within combinatorial treatment 
and it was successfully tested in vivo before [84] [85]. Our data suggest that V-ATPases 
also influence p53, so we combined V-ATPase inhibition through archazolid A and p53 
I. Introduction 
 
11 
 
activation through nutlin-3a for an evaluation in a murine tumor model with glioblastoma 
cells. 
 
Figure 8: Chemical structure of nutlin-3a [75] 
 
 
2.2. Simvastatin 
 
Simvastatin is synthesized by substituting CH3 for H at the 2' position from the natural 
product lovastatin which was originally isolated from Aspergillus tereus [86] [87]. The 
main and well-known function of statins is the lowering of cholesterol by inhibition of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which is responsible for 
the reduction from HMG-CoA to mevalonate which is then metabolized to cholesterol 
through a few further steps. Cholesterol is necessary, among other functions, for the 
production of steroid hormones, vitamin D, bile acids and lipoproteins. Cells must 
precisely regulate the balance of mevalonate synthesis to avoid sterol overaccumulation 
by two different mechanisms, feedback regulations and low-density-lipoprotein (LDL)-
receptors. A decrease of mevalonate production leads to an increase of LDL-receptors on 
the surface of hepatic cells, followed by the increasing intake of LDL into the liver cells 
and the lowering of LDL level in the blood [88]. Simvastatin was established in the late 
1980s as Zocor® (Merck Pharma), but now a variety of generic medicaments exist. For 
sure, simvastatin passed through a huge number of clinical studies [89] [90], up to now it 
is still frequently mentioned in new publications [91]. Animal and human clinical data 
suggest that simvastatin is twice as potent as lovastatin [92]. Next to influences on the 
cholesterol synthesis, there are more and more new properties of statins found concerning 
immunomodulation, neuroprotection, anti-inflammation and anti-cancer activities [93]. It 
was already demonstrated that simvastatin shows anti-tumor activity [94]. In human 
breast cancer cells, it inhibits cell proliferation, affects the cell cycle and induces 
apoptosis [95]. In this work, we evaluated the influence of simvastatin in combination 
with our natural compound archazolid A to evaluate the influences on the cholesterol 
metabolism in Huh7 tumors (hepatocellular carcinomas) in vivo.  
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Figure 9: Chemical structure of simvastatin [75] 
 
 
2.3. Sorafenib  
 
Sorafenib is a multiple kinase inhibitor which has been established on the market as 
Nexavar® (Bayer Pharmaceuticals) since 2006 [96]. It belongs chemically to a class that 
can be described as bis-aryl ureas [97]. Sorafenib is able to inhibit the serine-threonine 
kinase Raf which is part of the Ras/MEK/ERK pathway [98]. In addition, it is able to 
block the auto-phosphorylation of a variety of receptor tyrosine kinases [99]. It is 
effective against tumor growth through its anti-proliferative, anti-angiogenesis, anti-
metastatic and pro-apoptotic properties [100] [101]. Sorafenib is the only drug with 
clinical approvement for patients suffering from advanced stage hepatocellular carcinoma 
(HCC) [102]. HCC is an epithelial liver tumor, mostly with poor prognosis. Sorafenib is 
used as a cytotoxic drug for systemic treatment. It is orally administered and relatively 
well tolerated by patients up to a dosage of 400 mg which was tested in a phase III study 
with over 600 participants [103]. Sorafenib was able to improve the overall survival rate 
of patients suffering from advanced hepatocellular carcinoma [104]. This drug was 
already tested in a variety of in vitro and in vivo models. In murine models it showed the 
induction of vascular regression and inhibition of tumor growth, orally administered in 
dosages up to 100 mg/kg via gavage [105] [106]. But there are also other data on in vivo 
experiments which show proper results with an intraperitoneal application [107]. Since 
Cdk5 is known to play a role in HCC, we investigated the effect of sorafenib in 
combination with Cdk5 inhibition on Huh7 tumors. 
Figure 10: Chemical structure of sorafenib [75]  
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3. The role of Cdk5 in cancer development  
  
Some projects of our lab focus on the effects of  Cdk5 inhibition in cancer therapy. I 
contributed to some of these projects with in vivo experiments, so the role of Cdk5 in 
cancer development is explained in more detail in this section. 
Cyclin-dependent kinases (Cdks) are a family of serine/threonine kinases which are 
activated by cyclins. Nine Cdks and ten cyclins have been identified in humans but there 
are additionally several Cdk related kinases whose cyclin partner is not yet identified 
[108]. Cdk5, which is expressed in all tissues, is a very special member of this family 
because its kinase activity is activated by binding to the non-cyclin proteins p35 and p39 
which induces changes in the conformation of the kinase [109]. These activators are 
predominantly expressed in post-mitotic neurons which is the reason why Cdk5 is mainly 
associated with the central nervous system (CNS) [110]. These two activators regulate 
themselves through transcription and ubiquitin-mediated degradation. P35 and p39 can 
get cleaved to the more stable products p25 and p29 which increases the Cdk5 activation 
[111]. Cdk5 itself was first discovered during the 1990s to have certain functions in the 
CNS [112]. Its main influence concerns neuronal migration, axonal guidance and synaptic 
plasticity and it is also associated with a variety of neurodegenerative and 
neuropsychiatric diseases [113]. Its dysregulation by binding to p25 is associated with the 
development of amyotrophic lateral sclerosis and Alzheimer’s disease [114] [115]. Since 
the 1990s, a variety of other functions of Cdk5 have been evaluated. There are many 
molecular mechanisms Cdk5 uses to affect cellular processes in different cell types, 
associated with aberrant Cdk5 activity. It was shown that it regulates differentiation, 
exocytosis, gene expression and transcription, cell–cell and cell–matrix adhesion, cell 
migration, tissue regeneration, wound healing, senescence, angiogenesis, apoptosis and 
hormone regulation in non-neuronal cells [116] [117]. Cdk5 was discovered to play a 
significant role in different cancer types including lung cancer, prostate cancer, pancreatic 
cancer, breast cancer and glioblastomas [118]. Our group was able to show the profound 
functions of Cdk5, that it is increased in human HCC tissues [111] and that it plays a role 
in vascular development [113].  
Several murine tumor experiments in this thesis were established to investigate the 
potential of Cdk5 inhibition as anti-cancer strategy. 
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Figure 11: Cellular processes regulated by Cdk5 [112] 
 
 
4. Murine tumor models in cancer research 
 
Laboratory animals are widely used in research, according to the BMEL, 2.798.463 
animals were used in its purpose in Germany in 2014. 83% of all of them are allotted to 
rodents as mice and rats.  
Murine models have always played a significant role in cancer research for many decades 
and are indispensable in the drug discovery and developmental process for new anti-
cancer drugs, small molecules and biologics [119]. Models which are mostly used include 
xenografts, meaning that a graft of tissues is taken from a donor of one species and is 
grafted into a recipient of another species, and allografts, meaning that a graft of tissues is 
taken from a donor of one species and is grafted into a recipient of the same species, 
grown in either immune competent or immune deficient mice. But nowadays, transgenic, 
knock-out and knock-in mouse models become established more and more to evaluate the 
pathways and targets in anti-cancer therapy [120]. Animal models can provide 
information on pharmacodynamics and pharmacokinetics and provide pharmacological 
and biological information on anti-cancer drugs. They are used to identify the 
pathophysiology of cancer including new target identification, to identify novel 
therapeutic agents, to explore the utility of novel therapeutics combined with established 
therapeutic regimes and to study mechanisms of intrinsic and acquired resistance to 
cytotoxic and targeted therapies [119]. There exist a variety of animal models in cancer 
research, beginning with toxicology tests to determine parameters such as LD50 (median 
lethal dose), TD50 (median toxic dose), LOEL (lowest observed effect level) and NOEL 
(no observed effect level) to evaluate the toxicity of a certain anti-cancer drug in vivo, 
followed by studies on pharmacokinetics and dynamics to evaluate the behavior of the 
substance in the body and to find an adequate administration regime. According to this, 
we performed experiments concerning pharmacokinetics with the compounds archazolid 
A and roscovitine. After this, planning an experiment leads to the decision which dosage 
is suitable enough to use it in a murine tumor model. In this thesis, these kind of 
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experiments are called “dose finding“ because we wanted to evaluate suitable dose rates 
which the mice would tolerate during long-term experimental periods. We conducted this 
with many of our compounds. The next step was to establish tumor models concerning 
tumor growth or dissemination. Two classes of animal models are used widely, the 
ectopic tumor model where the mouse receives tumor cells via subcutaneous, 
intraperitoneal or intravenous injection, not into the original organ of tumor cells. Within 
the other one, the orthotopic model, the tumor cells are implanted into the organ of their 
origin [119]. In this thesis, ectopic xenografts with a variety of human cancer cell lines 
and two ectopic allograft models with luciferase-tagged murine breast cancer cells or 
murine melanoma cells were used. Partly using bioluminescence imaging for their 
evaluation. The advantage of our murine tumor models is that the experimental drugs 
were able to be tested under the physiological influences of a living organism, e.g. the 
general condition of the animals, their gender or corresponding hormones. This is not 
possible with in vitro experiments were cell layers are used. For the use of murine cancer 
cell lines we chose the mouse strains were they originated from to work with syngeneic 
models. But a variety of human cancer cell lines were also used to evaluate our 
experimental compounds. This was even possible because we used immuno-deficient 
mouse strains in which human cancer cells were able to grow. In this way, information 
can be gained in murine experiments to enable conclusions how human cancers could 
respond to a certain treatment. But it has to be mentioned that murine models alone are 
not suitable for a complete preclinical evaluation of an experimental drug. This is the 
reason why in preclinical studies always two different animal species have to be used for 
testings. Murine models are established as a start, they are very important to gain first in 
vivo results and to lay the foundations for further experiments.  
 
 
5. Aim of the thesis 
 
Our lab focuses on new pharmaceutical anti-cancer approaches, namely the use of natural 
compounds (DFG, FOR 1406) and synthetic compounds as potential novel anti-cancer 
drugs. A variety of in vitro experiments were performed by my colleagues to investigate 
the anti-cancer potential of the experimental drugs. I carried out the next step, namely the 
corresponding animal experiments. The aim of this thesis was the establishment, 
realisation and evaluation of all performed murine tumor experiments. In detail, the 
establishment of the experimental setups, the choice of mouse strains, the realisation of 
all experiments up to the generation and interpretation of the results. The profound testing 
of the anti-cancer compounds was enabled through the in vivo experiments in this thesis. 
Additionally, all methods for the usage of the bioluminescence imager IVIS® Spectrum 
within the murine experiments were established for the very first time at our lab and 
offered the possibility to use a non-invasive and repeatable imaging tool for tumor 
dissemination models. It is very important to visualize the dissemination of tumor cells in 
the body to identify the organs they invade and where they are able to form new growths. 
The demonstration of tumor cell dissemination in a living animal over time, where mice 
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do not have to be sacrificed, was realised for the first time in our lab by use of this 
bioluminescence imager. 
In general, all of the animal experiments in this thesis can be described as models to 
investigate attempts to hamper tumor growth or dissemination through natural and 
synthetic chemotherapeutics in vivo, partly with closer inspection on the influence of 
Cdk5 in cancer processes. The aim was to provide tools to develop new anti-cancer 
strategies and to reach profound results through in vivo experiments. 
When an experimental compound was used in vivo for the first time, a dose-finding 
experiment was performed in the beginning. The aim of these trials was to evaluate a 
suitable treatment regime and a dosage mice tolerate during long-term experiments. 
Studies on pharmacokinetics were performed to evaluate the concentration of a substance 
in the blood over time after injection and to adjust our treatment regimes according to the 
results. 
The aim of this thesis was to establish suitable murine tumor models for our projects. 
Suitable allograft and xenograft models were needed for the evaluation of the effects on 
tumor growth of some of the experimental compounds (archazolid A, LGR 2674, PS89 
and soraphen A). Additionally, two murine models were established to investigate the 
potential of the experimental compounds tetrandrine and soraphen A on hampering tumor 
dissemination.  
To evaluate the influence of cancer stem cells on tumor development and growth, two 
murine limiting dilution experiments were performed. And to further investigate Cdk5‘s 
role in cancer different murine tumor growth experiments were established.  
All in all, the aim of this thesis was to establish and use in vivo models in order to 
investigate the effects of experimental compounds on tumor growth and tumor 
dissemination.  
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II. Materials and Methods 
 
 
1. Materials 
 
1.1. Compounds 
 
Archazolid A  Prof. Dirk Menche (University of Bonn, Germany) 
Dinaciclib  Selleckchem (Munich, Germany) 
LGR 2674 Dr. Vladimir Krystof (Palacky University of Olomouc, 
Czech Republic)   
Nutlin-3a   MedChemExpress (Princeton, USA) 
PS89                                       Prof. Uli Kazmaier (University of Saarland, Germany) 
Roscovitine   LC Laboratories (New Boston, USA) 
Simvastatin   Sigma Aldrich (Taufkirchen, Germany) 
Sorafenib   LC Laboratories (New Boston, USA) 
Soraphen A   Prof. Rolf Müller (University of Saarland, Germany) 
Tetrandrine                            Santa Cruz Biotechnology (Santa Cruz, USA) 
 
 
1.2. Cell culture  
 
B16F1 cells                            ATCC (Wesel, Germany) 
Huh7 cells DSMZ (Braunschwaig, Germany)  
Huh7 nt shRNA cells generated by Dr. Sandra Ehrlich (University of Munich, 
Germany) 
Huh7 Cdk5 shRNA cells     generated by Dr. Sandra Ehrlich (University of Munich, 
Germany) 
U87MG  cells  Prof. Adrian Harris (Oxford University, United 
Kingdom) 
Jurkat-luc cells  Dr. Irmela Jeremias (Helmholtz Centre Munich, 
Germany) 
T24 nt shRNA cells  generated by Dr. Siwei Zhang (University of Munich, 
Germany) 
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T24 Cdk5 shRNA cells generated by Dr. Siwei Zhang (University of Munich, 
Germany) 
4T1-luc cells Perkin Elmer (Rodgau, Germany) 
RPMI 1640 medium Pan Biotech (Aidenbach, Germany) 
DMEM medium Pan Biotech (Aidenbach, Germany) 
McCoy’s 5A medium            Pan Biotech (Aidenbach, Germany)  
Glutamine                              Roth (Karlsruhe, Germany)  
Collagen G                             Biochrom AG (Berlin, Germany)  
Fetal calf serum (FCS) Biochrom AG (Berlin, Germany) 
Puromycin Sigma Aldrich (Taufkirchen, Germany) 
Pyruvate   VWR  (Ismaning, Germany) 
Cremophor® (solutol)            Sigma Aldrich (Taufkirchen, Germany) 
DMSO AppliChem (Darmstadt, Germany) 
NaCl                                       Bernd Kraft (Duisburg, Germany) 
Na2HPO4                                Grüssing (Filsum, Germany) 
KH2PO4                                  Merck (Darmstadt, Germany) 
EDTA                                     Roth (Karlsruhe, Germany) 
Trypsin                                   Pan Biotech (Aidenbach, Germany) 
PBS (pH7.4) NaCl 132.2mM + Na2HPO4 10.4 mM + KH2PO4 3,2 
mM + H20 (in house) 
Trypsin/EDTA (TE)  Trypsin 0.05 % , EDTA 0.20% , PBS (in house)  
Cell culture flasks/plates Sarstedt (Nümbrecht, Germany) 
 
 
1.3. In vivo experiments 
 
NaCl 0,9%   Braun AG (Melsungen, Germany) 
Acetone   Brenntag GmbH (Munich, Germany) 
Ethanol   Brenntag GmbH (Munich, Germany) 
Bepanthen®   Bayer Vital GmbH (Leverkusen, Germany) 
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Isothesia®   Henry Schein Vet (Hamburg, Germany) 
Lasal 2003 Oxygen  Air Liquide (Munich, Germany) 
Ketamine 10%  beta-pharm (Vechta, Germany) 
Xylariem®   Ecuphar (Oostkamp, Belgium) 
Tamoxifen   Sigma Aldrich (Taufkirchen, Germany) 
Syringes   Henry Schein Vet (Hamburg, Germany) 
Needles   Terumo (Leuven, Belgium) 
Scalpels   Dahlhausen (Cologne, Germany) 
Matrigel®   Corning (Bedford, USA) 
D-Luciferin, potassium salt Perkin Elmer (Waltham, USA) 
Paraformaldehyde (PFA) AppliChem (Darmstadt, Germany)   
EDTA blood tubes Sarstedt (Nümrecht, Germany) 
 
 
1.4. Laboratory mouse strains 
 
1.4.1. C57BL/6 
These black mice (C57BL/6JOlaHsd) were purchased from Envigo, former Harlan 
Laboratories (Eystrup, Germany) or taken from our own breeding. This is an inbread 
strain which has a competent innate and adaptive immune system.  
 
1.4.2. BALB/c  
These albino mice (BALB/cOlaHsd) were purchased from Envigo, former Harlan 
Laboratories (Eystrup, Germany). This is an inbread strain which has a competent 
innate and adaptive immune system.  
 
1.4.3. BALB/c nu/nu  
These nude mice (BALB/cOlaHsd-Foxn1
nu
) were purchased from Envigo, former 
Harlan Laboratories (Eystrup, Germany). They are hairless with an albino 
background. These mice are T-cell deficient and the nu allele on chromosome 11 
holds an autosomal recessive mutation which is responsible for the hairlessness.  
 
1.4.4. Scid 
This albino immunodeficient strain (CB17/lcr-Prkdc
scid
/lcrCrl) was purchased from 
Charles River Laboratories (Sulzfeld, Germany). They hold the autosomal recessive 
scid mutation (severe combined immunodeficiency). This mutation affects B- and T-
cell production, while their innate immune system is intact.  
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1.4.5. Nod Scid  
These albino immunodeficient mice (Nod.CB17-Prkd
scid
/NCrHsd) were purchased 
from Envigo, former Harlan Laboratories (Eystrup, Germany). They hold the scid 
mutation, so they have no mature B- and T-cells. They also have a reduced innate 
immune system including deficits in macrophages, dendritic and natural killer cells 
and the complement system.  
 
1.4.6. NSG (Nod Scid Gamma)  
This albino immunodeficient strain (Nod.Cg-Prkd
scid
Il2rg
tm1Wjl
/SzJ) was purchased 
from Charles River Laboratories (Sulzfeld, Germany). Their scid mutation prevents 
maturation of T- and B-cells, they hold deficiencies in their innate immune system as 
the absence of hemolytic complement, reduction of dendritic cell function and 
defective macrophages. There is also a deficit in Il2rg which prevents the signaling 
from six interleukins and blocks the development of natural killer cells.  
 
1.4.7. Housing   
Mice were housed in a special air-conditioned room within individual ventilated 
cages (IVC, type II long, Tecniplast). A 12h day- and night cycle was provided. All 
of the mice had ad libitum access to autoclaved water (in bottles) and autoclaved 
standard food (producer: Ssniff). The maximum occupancy was five animals per 
cage. The cages, inclusive litter and bedding inlets, were changed once a week. 
Mice were purchased at an age of five weeks and used at the earliest with six weeks 
in the experiments to have enough time to acclimatize and to adapt to the new 
housing conditions. In the animal facility, the health status was checked quarterly 
according to FELASA recommendations.  
All animal experiments were performed according to German legislation for the 
protection of animals and were approved by the government of Upper Bavaria. 
 
 
1.5. Instruments 
 
Canon Digital IXUS 70  Canon (Krefeld, Germany) 
Digital Caliper Emil Lux (Wendelskirchen, Germany) 
Grundig MC4541 shaver   Grundig (Fürth, Germany) 
IVIS® Spectrum Caliper Life Sciences (Rüsselsheim, Germany) 
Megafuge 1. ORS Heraeus (Hanau, Germany) 
Olympus CK30 microscope Olympus (Hamburg, Germany) 
Scale TE601  Sartorius (Göttingen, Germany) 
UV- lamp  Philips (Hamburg, Germany) 
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Vi-Cell TM XR Beckmann Coulter (Fullerton, USA) 
 
 
1.6. Software 
 
Graph Pad Prism 5.04  Graph Pad (San Diego, USA) 
Living Image 4.4 Caliper Life Sciences (Rüsselsheim, Germany)  
 
 
2. Methods 
 
2.1. Cell culture  
 
All tumor cell lines which were used for our animal experiments were chosen 
according to prior in vitro experiments. Human hepatocellular carcinoma cells 
(Huh7) were cultivated in DMEM medium, supplemented with 10% FCS. The stable 
lentiviral knock-down in Huh7 nt shRNA and Huh7 Cdk5 shRNA was generated by 
Dr. Sandra Ehrlich (University of Munich, Germany), these cells were grown in 
DMEM medium which contained 10% FCS and 1% puromycin. B16F1 (murine 
melanoma cells) were cultured in DMEM medium, supplemented with 10% FCS. 
Stable luciferase expressing murine breast adenocarcinoma cells (4T1-luc) and the 
human glioblastoma cell line (U87MG) were cultivated in RPMI 1640 medium 
containing 10% FCS. The stable luciferase-expressing human leukemia cells (Jurkat-
luc) were grown in RPMI 1640 medium containing 10% FCS and 1% pyruvate. The 
stable lentiviral knock-down in the human urinary bladder cancer cells T24 nt 
shRNA and T24 Cdk5 shRNA was generated by Dr. Siwei Zhang (University of 
Munich, Germany). These cells were grown in McCoy’s 5A medium which 
contained 10% FCS, 1% glutamine and 1% puromycin. All cells were cultured under 
constant humidity at 37°C and with 5% CO2 in an incubator. The culture flasks for 
all Huh7 lines were first coated with collagen G (0.001% in PBS) before seeding. 
For all animal experiments 150 cm
2
 flasks were used. Adherent cells were used when 
they were confluent, their medium was removed and cells were washed two times 
with PBS before incubation with trypsin/EDTA (TE) for about 2 min at 37°C to 
harvest them. This reaction was inactivated again with growth medium. Afterwards 
the cells were counted via Vi-Cell TM XR cell counter. The required amount of cells 
was taken off and centrifuged (1.000 rpm, 5 min, 20°C), then the cell pellet was 
solved again with PBS. U87MG cells and T24 cells were diluted 1:1 in Matrigel® 
and PBS in terms of better propagation of tumors prior to injection. 
Cells in suspension (Jurkat-luc) were cultivated in growth medium, then counted via 
Vi-Cell TM XR. The required amount was taken off and centrifuged (1.000 rpm, 5 
min, 20°C), afterwards the cell pellet was re-suspended in PBS. 
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2.2. In vivo experiments 
 
All laboratory mice were purchased at an age of five weeks. They were used at the 
earliest with an age of six weeks for the experiments. Tumor cells for all in vivo 
experiments were cultured and prepared as described above. 
Hairy mice were locally shaved before cell inoculation. Subcutaneous (s.c.) 
injections of tumor cells into the mice‘ flanks and intraperitoneal (i.p.) injections of 
substances were carried out with 1 ml syringes in combination with 27 Gauge (G) 
needles. Before intravenous (i.v.) injections, the tail veins were dilated with an UV 
lamp and 1 ml syringes and 27 G needles were used for this procedure. General 
condition of the mice was checked daily, body weight was measured at least once a 
week with a scale and tumor growth was measured every second to third day with a 
caliper. For intravenous applications, the injection volume did not exceed 100 µl 
while the volume for subcutaneous and intraperitoneal injections varied between 100 
µl and 200 µl. In the end of all in vivo experiments mice were sacrificed through 
cervical dislocation. Solid tumors were removed, weighed, photographed and split 
into two parts, one for storage at -80°C and one for conservation in 1% 
paraformaldehyde (PFA). 
 
 
2.2.1. In vivo imaging system (IVIS®) 
 
For bioluminescence imaging experiments with the IVIS® Spectrum, all mice were 
anesthetized with isoflurane in oxygen, during the beginning with 2-3 % in a 
chamber and for maintenance with 1.5-2 % through nose cones. Eye ointment 
(Bepanthen®) was used to prevent the cornea drying out. During imaging, mice lay 
on a warm board. Five to ten minutes before imaging 6 mg K-luciferin per mouse, 
solved in 100µl PBS, were intraperitoneally injected. Adjustments for the IVIS® 
Spectrum: 3-6 sequenced pictures with a delay time of 0.5-2 min were taken. 
Exposure time 1 sec, Binning 8, F-Stop 1, if not indicated otherwise. For evaluation 
of bioluminescence signals ROIs (region of interest) were defined and the total signal 
per ROI was calculated as photons/second/cm
2
 (total flux/area). Shown is always one 
picture out of a sequence.  
Method is based on the reaction between the luciferase in the cells and the injected 
luciferin which led to a bioluminescence signal the imager can detect [121]. 
Luciferin is oxidized by the enzyme luciferase under ATP spending and under the 
presence of oxygen to form an electronically excited oxy-luciferin structure. Visible 
light is emitted following the relaxation of excited oxy-luciferin to its ground state. 
Because this light can be transmitted through mammalian tissues, it is possible to use 
bioluminescence for non-invasive and quantitative monitoring of tumor burden 
[122]. 
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2.2.2. Preliminary dose finding experiments 
 
Dose finding experiments were performed for the compounds simvastatin, PS89, 
LGR 2674, soraphen A, archazolid A and nutlin-3a, partly within combinatorial 
treatment regimes. For evaluating their toxicity in living mice and to find a proper 
dosage, all substances were solved in 5% DMSO, 10% solutol and 85% PBS and 
were intraperitoneally injected using 1 ml syringes and 27 G needles. Volume of 
injection always amounted 100 µl per mouse. For all experiments, female mice at an 
age of six weeks were used. Mice were controlled at least directly after injection, 30 
minutes later, two hours later, 24 hours later and then daily. Their general condition 
was evaluated by their breathing, behavior, posture, weight and body condition score 
(BCS), by signs of pain as bent position, closed eyes and isolation of the group and 
by their fur and color of the skin and mucosa (eyes and anus). Mouse strains were 
chosen according to the cell lines they should get applied in the main trials. 
 
 
2.2.2.1. Simvastatin 
For the dose finding test with simvastatin, two female Scid mice received a daily 
dose of 10 mg/kg over five days, method is described above. They received the first 
dosage on day 0 and the experiment was ended on day 4 through cervical dislocation. 
A second experiment was performed with another two female Scid mice that 
received 10 mg/kg simvastatin in combination with 0.2 mg/kg archazolid A via daily 
intraperitoneal injection, also over five days. Mice were kept under close meshed 
surveillance, all mice were sacrificed at the end of the experiment (d4) through 
cervical dislocation. 
 
2.2.2.2. LGR 2674 
The roscovitine derivative LGR 2674 was tested in two dose rates over five days, 1.5 
mg/kg and 15 mg/kg per day. In both settings two female Scid mice were used which 
received a daily intraperitoneal injection. At the end of the experiment (d4) mice 
were sacrificed through cervical dislocation 
 
2.2.2.3. Archazolid A and nutlin-3a 
Archazolid A was tested four times, dosages lay at 0.25 mg/kg/d, 0.3 mg/kg/d, 0.45 
mg/kg/d and 0.6 mg/kg/d.  
First, from a group of three BALB/c nu/nu mice, always one mouse received either 
0.3 mg/kg archazolid A or 5 mg/kg nutlin-3a or a combination of both via daily i.p. 
injection over five days (d0, d1, d2, d3, d4).  
Afterwards, the dosage of archazolid A was varied, 0.3 mg/kg, 0.45 mg/kg and 0.6 
mg/kg were tested, each in one mouse via daily i.p. injection over five days.  
In the third part of this experiment, 0.25 mg/kg and 0.3 mg/kg archazolid A were 
tested daily over five days via i.p. injection, each in one BALB/c nu/nu mouse. At 
last, 0.25 mg/kg archazolid A in combination with 5 mg/kg nutlin-3a and 0.3 mg/kg 
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archazolid A in combination with 5 mg/kg nutlin-3a were evaluated, each 
combination in one BALB/c nu/nu mouse daily over five days.  
Their vitality was checked close meshed. On final days mice were sacrificed through 
cervical dislocation. 
 
2.2.2.4. PS89 
The substance PS89 was tested in three different dose rates, 10 mg/kg, 20 mg/kg and 
30 mg/kg. In each experiment two female Scid mice received a daily intraperitoneal 
injection. 10 mg/kg and 20 mg/kg were tested over four days (d0-d3), and the 30 
mg/kg dosage was evaluated over seven days (d0-d6). Afterwards a combination of 
30 mg/kg PS89 and 10 mg/kg sorafenib was tested in two female Scid mice daily 
over three days (d0-d2). On final days, mice were euthanised through cervical 
dislocation. 
 
2.2.2.5. Soraphen A 
A 5 mg/kg, a 10 mg/kg and a 20 mg/kg dosage was used for soraphen A testing. In 
each experiment two BALB/c mice received a daily i.p. injection over four days (d0-
d3). We also tested 20 mg/kg and 40 mg/kg of soraphen A in two female Scid mice 
each, which received a daily i.p. injection over five days (d0-d4). All mice were 
euthanised through cervical dislocation afterwards.  
 
 
2.2.3. Murine models concerning pharmacokinetics 
 
2.2.3.1. Archazolid A 
To evaluate the blood concentration of archazolid A after i.p. and i.v. injection, ten 
C57BL/6 mice, female and 12 months old, were used. Eight of these mice were 
divided into two groups (n=4), in the one group each mouse received an 
intraperitoneal injection of archazolid A (0.3 mg/kg), in the other group they 
received the same dosage intravenously via tail vein. In both groups, archazolid A 
was solved in an amount of 100 µl, consisting of 5% DMSO, 10% solutol and 85% 
PBS. 30 min, 1 hour, 2 hours and 6 hours later blood was taken via heart punction 
with 3 ml syringes and 27 G needles, for that mice were anesthetized with a 
combination of ketamine and xylazine (1 ml ketamine + 0.25 ml xylazine + 6 ml 
NaCl, then using 0.1 ml per 10g body weight). At each time-point blood was taken 
from one intraperitoneally treated and one intravenously treated mouse. After heart 
punction mice were euthanized through cervical dislocation. The other two mice did 
not get an archazolid A injection, but blood was also taken from them via heart 
punction, method is mentioned above. One sample stayed clear and was used as an 
internal standard (0% value) and the second one was armed with 10 µM archazolid A 
and was used as the 100 % value. All blood samples were centrifuged, serum phase 
was taken off and mixed 1:1 with acetone, centrifuged again and then, the upper 
phase containing archazolid A was taken off and frozen at -80° C for analysis. All 
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analyses, high performance liquid chromatography (HPLC) and mass spectrometry 
were performed by Dr. Jennifer Herrmann (University of Saarland, Germany). For 
our calculation of theoretical values which should be found in the blood, the formula 
n = m/M, (n = blood concentration, m = amount of the substance, M = molecular 
weight) was used. Based on the assumption of 1600 µl blood per mouse, consisting 
of 800 µl serum and 800 µl blood cells. The calculation we made is described in 
detail in the following: Molecular weight of archazolid A lays at 737. 98 g/mol, we 
injected 0.3 mg/kg archazolid A which equates 6 µg archazolid A per 20g mouse 
(standard mouse). The 6 µg are contained in 800 µl serum, following that 1 µl serum 
contains 7.5 ng archazolid A. Using the formula n = m/M, n = 7.5 ng/ 737.98 g/mol, 
n = 10 µM. All results were compared with this calculated value.  
 
 
2.2.3.2. Roscovitine 
To evaluate the concentration of roscovitine in murine blood samples after i.p. 
injection, 21 C57BL/6 mice, female and six weeks old, were used. 18 of these mice 
received an intraperitoneal injection of 150 mg/kg roscovitine, solved in 100 µl 
consisting of 5 % DMSO, 10 % solutol and 85 % PBS. 10 minutes, 20 minutes, 30 
minutes, 60 minutes, 2 hours and 4 hours later blood was taken from three mice at 
each time-point via punction of the heart, mice were anesthetized for that with the 
ketamine/xylazine combination mentioned before. Used were 3 ml syringes and 27 G 
needles. After the blood take, mice were sacrificed through cervical dislocation. The 
blood of the other three mice was taken in the same way, it was used as an internal 
standard, those mice were all vehicle treated before. All blood samples were taken 
into EDTA blood tubes to prevent coagulation. All following analyses, HPLC and 
mass spectrometry were performed by Dr. Christoph Müller (University of Munich, 
Germany). We performed calculations on the theoretical concentration which should 
be found in the blood, method is described in the following: We injected 150 mg/kg 
roscovitine per mouse which equates 3 mg/ 20g mouse (standard mouse). Based on 
the assumption of 1600 µl blood per mouse, there are 3 mg roscovitine in 1.6 ml 
blood equating 1.875 mg in 1 ml blood. All results were compared with this 
calculated value. 
 
 
2.2.4. Murine tumor models for tumor growth evaluation 
 
These experiments were performed following a general procedure. Hairy mice were 
shaved one to two days before the experiment started. All mice received the cells via 
subcutaneous injections into the left flank using 1 ml syringes and 27 G needles, if 
not indicated otherwise. Tumor growth was measured every second day with a 
caliper using the formula  π/6 x L x W x H (L = length, longest side of the tumor, 
W= width, widest side vertical to L, H= height). On final days of the experiments, all 
mice were sacrificed through cervical dislocation. Tumors were resected, weighed, 
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photographed and split into two parts, one for freezing at -80 C° and one for 
conservation in 1 % PFA. 
 
 
2.2.4.1. Effect of archazolid A treatment on murine breast cancer shown in an 
allograft tumor model 
For evaluating the effect of archazolid A on tumor growth of 4T1-luc cells, eight 
BALB/c nu/nu mice, female and six weeks old were used. 1 x 10
6
 4T1-luc cells per 
mouse, solved in 100 µl PBS, were injected. After that, mice were randomly divided 
into two groups (n=4). Therapy started on day six after cell inoculation. Archazolid 
A, solved in 5% DMSO, 10% solutol and 85 % PBS, was daily given in a dose of 0.3 
mg/kg via intraperitoneal injection, volume lay at 100 µl. Therapy was conducted 
seven times after cell application (d6, d7, d8, d9, d10, d11, d12), one group was 
treated with archazolid A, the other group was vehicle treated at the same points of 
time. Over a period of 12 days the average tumor volumes of both groups were 
measured and compared. Final day of experiment was day 13. 
 
 
2.2.4.2. Combinatorial effect of simvastatin and archazolid A on HCC tumors 
evaluated in a xenograft tumor model 
Regarding the combinatorial effect of simvastatin and archazolid A, a Scid mouse 
model was used. 32 female and six weeks old Scid mice received 3 x 10
6
 Huh7 cells 
for injection. Tumor bearing mice were randomly divided into four groups (n=8). 
Concerning therapy, volume of injection amounted 100 µl, both substances and the 
combination of both were solved in 5% DMSO, 10% solutol and 85% PBS. One 
group of mice was treated as a control and received vehicle, the simvastatin group 
got 10 mg/kg while the archazolid A group got 0.2 mg/kg. The fourth group was the 
combinatorial group which received both compounds in the dosage mentioned 
before. The intraperitoneal treatment started on day seven after cell injection and was 
daily continued until day 17. Mice received an injection 11 times (d7, d8, d9, d10, 
d11, d12, d13, d14, d15, d16, d17). Experiment was ended on day 17. 
 
 
2.2.4.3. Effects of combinatorial treatment of nutlin-3a and archazolid A on 
glioblastoma tumors using a xenograft model 
The combinatorial effect of nutlin-3a and archazolid A was tested in a xenograft 
BALB/c nu/nu mouse model. 32 female BALB/c nu/nu mice at an age of six weeks 
got 5 x 10
6
 U87MG cells injected. Volume of injection amounted 100 µl, cells were 
solved in 50% PBS and 50% Matrigel®. All mice were separated into four groups 
(n=8). One group was vehicle treated and used as control, another group was treated 
with archazolid A (0.2 mg/kg), the third group received a daily dosage of nutlin-3a 
(5mg/kg) and the last one received a daily combinatorial dosage of archazolid A 
(0.2mg/kg) and nutlin-3a (5 mg/kg), all substances were solved in 5% DMSO, 10% 
solutol and 85% PBS. Therapy started on day seven after cell application and was 
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performed 16 times, that means daily until day 25. Experiment was ended on day 25. 
The evaluation of tumor growth over time was performed by jun.-Prof. Thorsten 
Lehr (University of Saarland, Germany). The modeling was performed using the 
non-linear mixed effects modeling technique with the software NONMEM 7.3. 
[123], nutlin-3a PK model was built based on literature data. [84] Tumor growth 
curves were normalized to control. 
 
 
2.2.4.4. Effect of LGR 2674 on HCC tumors using a xenograft setup 
The effect of the roscovitine derivative LGR 2674 on tumor growth was evaluated 
with Huh7 cells using a Scid mouse model. 20 female mice at an age of six weeks 
were chosen. 3 x 10
6
 Huh7 cells per mouse were solved in 100 µl PBS and then s.c.  
injected. Tumor bearing mice were randomly divided into two groups, one control 
group (n=10) and a LGR 2674 treatment group (n=10). The control group was daily 
vehicle treated while the therapy group received LGR 2674 in a dosage of 1.5 mg/kg 
solved in 5% DMSO, 10% solutol and 85% PBS every day. Therapy started on day 
eight after tumor cell inoculation, mice got their daily intraperitoneal injection 13 
times (d8, d9, d10, d11, d12, d13, d14, d15, d16, d17, d18, d19, d20). One mouse of 
the control group and one mouse of the LGR 2674 treated group had to be taken out 
of the experiment on day 17 because their tumor’s volume exceeded 1000 mm
3
. 
Final day for the other animals was day 20. 
 
 
2.2.4.5. Evaluation of the effect of PS89 in combination with sorafenib on HCC 
tumors using a xenograft model 
For evaluating the effect of PS89 in combination with sorafenib on tumor growth, 3 x 
10
6
 Huh7 cells were injected into Scid mice. These 32 female and six weeks old mice 
received the cells solved in a volume of 100 µl PBS.  Afterwards, mice were divided 
into four groups (n=8). Both substances and the combination of both were solved in 
5% DMSO, 10% solutol and 85% PBS, the control group received intraperitoneal 
injections of the vehicle, the PS89 treated group received 20 mg/kg and the sorafenib 
treated group 10 mg/kg. The fourth group got a combination of both substances, 
dosage as mentioned before. Treatment was carried out three times a week, it started 
on day ten and ended on day 19, so mice received five injections (d10, d12, d14, d17, 
d19). Experiment ended on day 19. 
 
 
2.2.4.6. Effect of soraphen A on HCC tumors shown in a xenograft tumor model 
For this experiment, 20 Scid mice, female and six weeks old were used. They 
received 3 x 10
6
 Huh7 cells. Volume of injection amounted 100 µl, cells were solved 
in PBS. Tumor bearing mice were divided into two groups (n=10). Therapy with 
soraphen A (40 mg/kg) started on day seven after cell inoculation. Mice received a 
daily dose of 40 mg/kg soraphen A, solved in 5% DMSO, 10% solutol and 85% PBS 
via intraperitoneal injection. The second group was treated as a control and received 
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solvent. Therapy started on day seven after cell application and was performed nine 
times (d7, d8, d9, d10, d11, d12, d13, d14, d15). Over a period of 15 days the 
average tumor volumes of both groups were measured and compared. On day 16 the 
experiment was ended. 
 
 
2.2.5. Murine tumor experiments concerning tumor dissemination 
 
2.2.5.1. Searching for a murine tumor model within a leukemia project  
For the Jurkat-luc leukemia experiment, three different mouse strains were used, 
Scid, Nod-Scid and Nod Scid Gamma (NSG) mice. From each strain we worked with 
three mice, female and six weeks old. 1 x 10
6
 Jurkat-luc cells per mouse were solved 
in 100 µl PBS and were injected via the tail vein. Veins were dilated by holding an 
UV lamp for circa 20 sec over the tail. We used 1 ml syringes and 27 G needles to 
inject the cells. For bioluminescence imaging, the imager IVIS® Spectrum was used, 
each group (n=3) was imaged together, the setup for imaging was described before. 
Imaging was performed several times. Nod-Scid and Scid mice were imaged six 
times (d4, d7, d11, d13, d19 and d21) up to final day (d21) after cell inoculation 
while NSG mice were imaged nine times (d2, d5, d8, d12, d15, d19, d22, d26, d29) 
until final day (d29). After the last imaging procedures, mice were sacrificed through 
cervical dislocation  
 
 
2.2.5.2. Effect of tetrandrine on tumor dissemination evaluated in three 
different murine experiments 
The dissemination of 4T1-luc cells under tetrandrine treatment was evaluated via 
three different experimental setups. For all of them, we used BALB/c mice, female 
and six weeks old. 1 x 10
5
 4T1-luc cells, solved in 100 µl PBS, were intravenously 
injected into the tail vein of each mouse. Tetrandrine was intraperitoneally applied, 
injection volume lay at 100 µl. The IVIS® Spectrum was used for bioluminescence 
imaging. Setup is described before. Ventrodorsal imaging positions were chosen, 
meaning mice lay on their backs during the imaging procedure. 
In the first setup 20 BALB/c mice were randomly divided into two groups (n=10), 
tetrandrine was solved in 5% DMSO, 10% solutol and 85% PBS. One group received 
tetrandrine (100 mg/kg) three times, 24h and 4h before cell application and 24h after 
it. The other group, used as a control, was vehicle treated at the same points of time. 
On day eight after cell injection bioluminescence imaging was conducted with 
IVIS® Spectrum and the experiment was ended through cervical dislocation of all 
mice. Lungs were extracted, imaged with IVIS® Spectrum and photographed. 
Organs were fixed in 1% PFA. 
 
Concerning the second setup, 24 BALB/c mice were randomly divided into three 
groups (n=8), tetrandrine was solved in sterile filtered 0.1 molar HCl this time. One 
group was vehicle treated and one group was treated with tetrandrine (100 mg/kg), 
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each group four hours before application of cells, directly after it and 20 hours after it 
a third time, both groups received just vehicle (DMSO) pre-treated 4T1-luc cells. 
While the third group got 4T1-luc cells injected which were pre-treated with 
tetrandrine (10 µM, 24h), those animals received one extra dose of tetrandrine 
directly after cell injection, at the other two points of time (4h before and 20h after 
cell application) they were vehicle treated. Imaging was performed eight days after 
cell inoculation with IVIS® Spectrum, four mice at a time. After imaging, all mice 
were euthanised through cervical dislocation.  
For the third setup 16 BALB/c mice were used, divided into two groups (n=8). One 
group, as a control, received vehicle (DMSO) pre-treated 4T1-luc cells, the other 
group received cells which were tetrandrine pre-treated (10µM, 24h) via tail vein 
injection. We imaged on day five and on day seven after tumor cell injection with the 
IVIS® Spectrum bioluminescence imager. Directly after the second imaging (d7) 
mice were sacrificed through cervical dislocation. 
 
 
2.2.5.3. Effect of soraphen A on tumor dissemination shown in an allograft 
tumor model 
In the metastasis experiment with soraphen A, 24 BALB/c mice were randomly 
divided into three groups (n=8), one as a control group received vehicle (ethanol) 
pre-treated 4T1-luc cells, one group received 4T1-luc cells with six hours pre-
treatment with soraphen A (1 µM)  and a third group received cells with 72 hours 
pre-treatment with soraphen A (25 nM). 1 x 10
5 
cells per mouse were solved in 100 
µl PBS and were injected via tail vein, four days respectively seven days later, mice 
were imaged with IVIS® Spectrum bioluminescence imager and the experiment was 
ended through cervical dislocation on day seven.  
 
 
2.2.6.  The influence of Cdk5 in cancer processes evaluated in murine tumor 
experiments  
 
2.2.6.1. Effect of Cdk5 knock-down in cells in combination with sorafenib 
treatment on HCC tumors evaluated in a Scid mouse model 
The effect of Cdk5 knock-down in tumor cells on tumor growth was tested in a Huh7 
and Scid mouse xenograft model. All cells for this experiment were generated by Dr. 
Sandra Ehrlich (University of Munich, Germany) through lentiviral transduction. 24 
female Scid mice at an age of six weeks were divided into four groups. In two groups 
each mouse got 3.3 x 10
6
 Huh7 nt shRNA cells, solved in 100µl PBS, injected into 
the left flank, after being locally shaved. The other two groups received the same 
amount of Huh7 Cdk5 shRNA cells. In the first Huh7 nt shRNA group (n=5, because 
one mouse did not develop a tumor) mice were treated as a control and received 
solvent consisting of 5% DMSO, 10% solutol and 85% PBS, the second group (n=6) 
received 10 mg/kg sorafenib solved in 5% DMSO, 10% solutol and 85% PBS via 
intraperitoneal injection. In the groups (n=6) which received the Huh7 Cdk5 shRNA 
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cells, one group was also treated with solvent as a control, the other group received 
10 mg/kg sorafenib. Daily intraperitoneal treatment started on day 11 after cell 
inoculation and lasted until day 18, so all mice received vehicle respectively 
sorafenib eight times during the experiment. Tumor volume was measured every 
second day with a caliper and calculated with the formula π/6 x L x W x H. On day 
18 all mice were sacrificed through cervical dislocation. Tumors were resected, 
weighed, photographed and split into two parts, one for freezing at -80 C° and one 
for conservation in 1 % PFA. 
 
 
2.2.6.2. Using Cdk5 knock-out mice and roscovitine treatment to evaluate their 
effects on melanoma cells 
For evaluating the effect of mice carrying an inducible endothelial Cdk5 knock-out 
in combination with roscovitine treatment on tumor growth, six Cdk5 knock-out 
mice (Cdk5 
fl/fl
 VECCre+) were used. All mice were provided by Dr. Johanna Liebl 
(University of Munich, Germany), for their creation a Cre-lox system was used. To 
induce the Cdk5 knock-out, mice were treated with tamoxifen (5mg/ml, 100 µl i.p. 
injection) over five days. After being locally shaved, each mouse received 1 x 10
6
 
B16F1 cells via subcutaneous injection into the left flank. Cells were solved in 100 
µl PBS. For this, 1 ml syringes and 27 G needles were used. Two groups of mice 
were formed. Three knock-out mice (Cdk5 
fl/fl
 VECCre+) were treated as a control 
and received solvent while the other three knock-out mice (Cdk5 
fl/fl
 VECCre+) were 
treated with roscovitine (150 mg/kg). Roscovitine was solved in 5% DMSO, 10% 
solutol and 85% PBS, an amount of 100 µl was intraperitoneally injected into the 
mice three times a week. Therapy started on day seven after cell inoculation. Tumor 
growth and tumor volume were measured three times a week with a caliper, using the 
formula π/6 x L x W x H. Experiment lasted 14 days altogether. On day 14, mice 
were sacrificed through cervical dislocation. Tumors were preserved as mentioned 
before. 
 
 
2.2.6.3. Limiting dilution experiment with T24 cells 
Regarding the effect of Cdk5 knock-down in T24 cells on tumor growth, 30 female 
BALB/c nu/nu mice at an age of six weeks were used. They were separated into two 
groups (n=15) which were divided again in three equal subgroups. All animals in one 
of the large groups (n=15) received T24 nt shRNA cells but each subgroup received 
a different amount of cells. The subgroups consisted of five animals, the first got just 
5 x 10
6
 cells subcutaneously injected into the left flank, the second group received 
2.5 x 10
6
 into their left flank and 1 x 10
5
 into their right flank, while the third group 
got 1 x 10
6
 cells injected into the left flank and 5 x 10
5
 cells into the right flank. 
Always used were 1 ml syringes and 27 G needles for the application. The same 
distributions were made for the 15 animals which received T24 shRNA Cdk5 cells. 
All cells were generated by Dr. Siwei Zhang (University of Munich, Germany) using 
lentiviral transduction. Each time, the cells were solved in 100 µl PBS mixed with 
II. Materials and Methods 
 
31 
 
100 µl Matrigel®. Tumor volume was measured three times a week with a caliper, 
using the formula π/6 x L x W x H. Measurement started on day four and lasted until 
day 42 after tumor cell inoculation. Mice were euthanized through cervical 
dislocation, tumor were preserved as mentioned above. 
 
 
2.2.6.4. Limiting dilution experiment with 4T1-luc cells 
In this experiment 50 BALB/c mice, female and six weeks old were locally shaved 
on their left flanks and got a subcutaneous application of 4T1-luc cells. Ten groups 
with five mice each were formed, two groups at a time received the same amount of 
4T1-luc cells. Injected were 1 x 10
6
, 1 x 10
5
, 1 x 10
4
, 1 x 10
3
 and 1 x 10
2 
cells, each 
solved in 100 µl PBS per mouse, using 1 ml syringes and 27 G needles for that. One 
of these two groups was then vehicle treated (100 µl, consisting of 5% DMSO, 10% 
solutol and 85% PBS), the other one received dinaciclib (30 mg/kg). Treatment was 
performed three times a week starting on the day of tumor cell application (d0) and 
was stopped on day 14. Tumor volumes were measured three times a week with a 
caliper in use of the formula π/6 x L x W x H. Bioluminescence pictures were taken 
with the IVIS® Spectrum on d3, d8, d15, d23 and d28. On day 25 after cell 
application, mice of both groups (control and dinaciclib) which received either 1 x 
10
6
, 1 x 10
5
 or 1 x 10
4
 cells were taken out of the experiment. The other mice, which 
received 1 x 10
3
 and 1 x 10
2 
cells were kept in the experiment and sacrificed on day 
30. The experiment was performed over 30 days altogether, ending with euthanasia 
through cervical dislocation on final day (d25 or d30), tumors were preserved as 
mentioned before. 
 
 
2.3. Statistical analysis 
 
Results are expressed as mean value ± S.E.M. Statistical analysis were performed 
with GraphPadPrism™, using unpaired t-tests for experiments with two groups and 
One-way ANOVA (Dunnett) for experiments with three or more groups to compare, 
if not indicated otherwise. P-values < 0.05 were considered as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
III. Results 
 
32 
 
III. Results 
 
 
1. Preliminary dose finding experiments in murine models 
 
The aim of the following experiments was to find dose rates of simvastatin, LGR 
2674, archazolid A, nutlin-3a, PS89 and soraphen A which different mouse strains 
would tolerate in our long-term main experiments with these experimental 
compounds concerning tumor growth and dissemination. All animal experiments 
were performed together with Kerstin Loske (technician, University of Munich, 
Germany) at the animal facility of AK Vollmar and AK Biel on the campus of the 
University of Munich in Großhadern. 
All of these substances have already shown promising results in vitro or were even 
evaluated in animal studies before. That was the basis for us to realize the following 
in vivo experiments. Dose rates were chosen according to former in vivo experiments 
performed at our lab, according to publications or in dependence on results of in vitro 
experiments with these substances. The toxicity and the tolerance of the compounds 
in vivo were evaluated with regard to the effects on the mice‘ general condition 
concerning their breathing, behavior, posture, signs of pain as bent position, closed 
eyes and isolation of the group, fur and color of the skin and mucosa (eyes and anus), 
body condition score (BCS) and body weight, which is the most meaningful 
parameter.  
For these preliminary experiments the same mouse strain we also wanted to use for 
the main experiment was chosen. This choice depended on the cell line which should 
subsequently be applied. Substances were solved in the same way as they were used 
afterwards for the injections in the main experiments (5% DMSO, 10% solutol, 85% 
PBS, composition is due to proper tolerance and solubility of substances in former in 
vivo experiments). After these preliminary dose finding experiments, simvastatin, 
LGR 2674, PS89 and soraphen A should be used in xenograft tumor models with 
Huh7 cells. This is a human cancer cell line, which only grows in immunodeficient 
mouse strains. Scid mice are B- and T-cell deficient and Huh7 cells grow very fast 
and reliable in this mouse strain, this is the reason why they were chosen and why we 
also performed these dose finding tests with them. The choice of a BALB/c nu/nu 
strain for the evaluation of archazolid A and nutlin-3a depends on the human 
glioblastoma cells (U87MG) which should be used for the corresponding tumor 
growth experiment. This is a human cell line which grows best in the T-cell deficient 
BALB/c nu/nu strain. Soraphen A should also be used for a tumor dissemination 
model with 4T1-luc cells, these murine breast cancer cells originate from BALB/c 
mice, so this is a syngeneic combination,which is why we chose this strain for such 
experiments. 
Due to the aim to minimize the numbers of experimental animals, we chose not more 
than two mice per dose finding test, because these experiments are just about 
preliminary information finding on which dosage could be suitable. Nevertheless, the 
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preliminary data gained in all of these experiments were useful tools for the planning 
of the corresponding main experiments because they gave us an orientation. 
 
 
1.1. Simvastatin 
 
Scid mice were chosen to evaluate the tolerance for simvastatin after intraperitoneal 
injections. The following therapy regime was performed over five days: 
n=2: 10 mg/kg simvastatin 
n=2: 10 mg/kg simvastatin combined with 0.2. mg/kg archazolid A 
 
All mice showed a proper general condition over the whole time of the experiment. 
The body condition score (BCS) retained at a value of 3, no loss of weight was 
detectable in the group receiving combinatorial treatment, mice receiving single 
simvastatin treatment constantly gained weight. (Figure 12) Both groups tolerated 
their treatments well. The consequence was to use exactly these dose rates of 
simvastatin, archazolid A and their combination for the main experiment (3.3. in this 
thesis).  
 
 
Figure 12.: Weight development over time. Weight of mice during the whole experimental period 
(d0-d4) either with daily simvastatin treatment (10 mg/kg) or daily combinatorial treatment (10 mg/kg 
simvastatin and 0.2 mg/kg archazolid A). Weight was assessed on first (d0) and last day (d4) of the 
experiment. Represented is the mean ± S.E.M. of two mice per group. 
 
 
1.2. LGR 2674 
 
To find a proper dosage for intraperitoneal injections of LGR 2674, Scid mice were 
chosen. Treatment regime over five days: 
n=2: 1.5 mg/kg LGR 2674 
n=2: 15 mg/kg LGR 2674 
 
In the group receiving 1.5 mg/kg, mice showed a reduction of body weight from the 
beginning of the treatment on, which still decreased during the ongoing experiment. 
Both mice showed signs of pain as horrent fur and a bent position. In the group 
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receiving 15 mg/kg, one mouse was found dead in the cage after the third treatment 
with substance, the other one suffered from harmful reduction of body weight 
(Figure 13) and also showed indications of pain as horrent fur and a bent position.  
These results led to the decision to use the lower dosage of LGR 2674 (1.5 mg/kg) 
for the main experiment (3.2. in this thesis) because this dosage was much better 
tolerated.  
 
Figure 13: Weight development over time. Weight loss of mice daily treated either with 1.5 mg/kg 
or 15 mg/kg LGR 2674 over five days (d0-d4). Weight was measured on day 0, day 2 and day 4 of the 
experiment. Represented is the mean ± S.E.M. of two mice per group (one within the 15 mg/kg 
treatment group on day 4). 
 
 
1.3. Archazolid A and nutlin-3a 
 
In this dose finding experiment, BALB/c nu/nu mice were chosen. Concerning 
archazolid A, four different dose rates were evaluated: 0.25 mg/kg, 0.3 mg/kg, 0.45 
mg/kg and 0.6 mg/kg. Nutlin-3a was single tested in a dose of 5 mg/kg and in 
combination with archazolid A. All compounds were intraperitoneally injected. 
Treatment regime in the first part of this experiment over five days (d0-d4): 
n=1: 0.3 mg/kg archazolid A 
n=1: 5 mg/kg nutlin-3a 
n=1: 0.3 mg/kg archazolid A combined with 5 mg/kg nutlin-3a 
Mice tolerated all of these dose rates well, no abnormalities in their general condition 
were detected. (Figure 14 A) 
 
In the second experiment, we administered a higher dosage of archazolid A because 
of the good tolerance in the prior experiment. Treatment regime in the second part of 
this experiment over five days (d0-d4): 
n=1: 0.3 mg/kg archazolid A 
n=1: 0.45 mg/kg archazolid A 
n=1: 0.6 mg/kg archazolid A 
Mice receiving 0.3 mg/kg and 0.6 mg/kg showed no changes in their behavior or 
wellness until the third treatment, on the fourth day of the experiment both mice were 
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found dead in their cage. The mouse receiving 0.45 mg/kg had unchanged 
parameters during the five day period of the experiment. (Figure 14 B)  
 
Concerning the deviant results of the 0.3 mg/kg dosage, a third experiment was 
performed. Treatment regime in this part of the experiment over five days (d0-d4): 
n=1: 0.25 mg/kg archazolid A 
n=1: 0.3 mg/kg archazolid A 
 
In this try, both mice showed an unchanged general condition during the experiment. 
(Figure 14 C) 
 
In a fourth part of this experiment, further combinations of archazolid A and nutlin-
3a were evaluated. Treatment regime over five days (d0-d5): 
n=1: 0.25 mg/kg archazolid A combined with 5 mg/kg nutlin-3a 
n=1: 0.3 mg/kg archazolid A combined with 5 mg/kg nutlin-3a 
Both compositions were tolerated well. Mice did not lose weight over time. (Figure 
14 D)  
The consequence of this experiment for us was to choose a 0.2 mg/kg dosage of 
archazolid A in the main experiment (3.6. in this thesis) to make sure that mice 
survive the long-time archazolid A treatment. This dose finding experiment also 
confirmed that 5 mg/kg of nutlin-3a is a dosage mice will tolerate over several days. 
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Figure 14: Weight development over time. A) Weight of mice in part one of this dose finding 
experiment, 0.3 mg/kg archazolid A, 5 mg/kg nutlin-3a and a combination of both were tested in one 
mouse each over five days. Weight was assessed on day 0, day 2, day 3 and day 4. Each curve 
represents one single mouse. B) Mice of part two, 0.3 mg/kg, 0.45 mg/kg and 0.6 mg/kg archazolid A 
were tested over five days. Weight was measured daily. Each curve represents one single mouse. C) 
Part three, 0.25 mg/kg and 0.3 mg/kg archazolid A were tested over a five day period, each dosage in 
one mouse. Weight was assessed daily. D) Part four, two combinatorial treatments were evaluated. 
0.25 mg/kg archazolid A with 5 mg/kg nutlin 3a and 0.3 mg/kg archazolid A with 5 mg/kg nutlin-3a, 
both over five days. Weight was assessed daily. Each curve represents one single mouse. 
 
 
1.4. PS89 
 
To assess a proper dosage for the i.p. use of PS89 in our tumor experiments, we 
evaluated three different dose rates over four days (d0-d3) in Scid mice: 
n=2: 10 mg/kg PS89 
n=2: 20 mg/kg PS89 
n=2: 30 mg/kg PS89 
Additionally, a combination of PS89 with sorafenib which was necessary for the 
main experiment (3.4. in this thesis) was evaluated over seven days (d0-d6):  
n=2: 30 mg/kg PS89 combined with 10 mg/kg sorafenib 
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During all these dose finding experiments, mice showed unchanged parameters 
concerning their general condition and a relatively constant body weight. BCS 
retained at a value of 3. Mice receiving 10 mg/kg and 20 mg/kg of PS89 gained little 
weight during the experimental period. (Figure 15) All dose rates of PS89 and the 
combination with sorafenib were tolerated well. For the main experiment (3.4. in this 
thesis) with PS89, we decided to use the medium dose rate of 20 mg/kg of PS89 and 
the evaluated 10 mg/kg of sorafenib to make sure all mice would endure the whole 
experimental period. 
 
Figure 15: Weight development over time. Mice were treated with different dosages (10 mg/kg, 20 
mg/kg, 30 mg/kg) of PS89 single or 30 mg/kg PS89 in combination with 10 mg/kg sorafenib. Weight 
was assessed daily. Represented is the mean ± S.E.M. of two mice per group. 
 
 
1.5. Soraphen A 
 
This compound was evaluated in a BALB/c strain as well as in a Scid strain 
performing i.p. injections, because it should be used later in different experiments. 
Treatment regime to evaluate the tolerance of soraphen A in BALB/c mice over four 
days (d0-d3): 
n=2: 5 mg/kg soraphen A 
n=2: 10 mg/kg soraphen A 
n=2: 20 mg/kg soraphen A 
All animals showed a proper general condition over the whole experimental period 
and changes in weight range were physiological. (Figure 16 A) All dose rates we 
evaluated were tolerated well.  
 
Treatment regime to evaluate the tolerance of soraphen A in Scid mice over five days 
(d0-d4): 
n=2: 20 mg/kg soraphen A 
n=2: 40 mg/kg soraphen A 
All animals showed a good general condition and weight fluctuated in physiological 
ranges during the five days of treatment. (Figure 16 B) For the main experiment (3.5. 
in this thesis) we used Scid mice and the higher dosage (40 mg/kg) of soraphen A. 
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Figure 16: Weight development over time: A) Weight of BALB/c mice daily treated with soraphen 
A (5 mg/kg, 10 mg/kg, 20 mg/kg) over four days. Weight was assessed on first (d0) and last (d3) day 
of experiment. Represented is the mean ± S.E.M. of two mice per group. B) Weight of Scid mice daily 
treated with soraphen A (20 mg/kg or 40 mg/kg) over five days. Weight was measured three times 
(d0, d2, d4). Represented is the mean ± S.E.M. of two mice per group. 
 
 
2. Murine experiments for pharmacokinetic studies 
 
These kind of animal experiments were established to extend our knowledge on the 
pharmacokinetic properties of V-ATPase inhibitor archazolid A and Cdk inhibitor 
roscovitine to evaluate their blood levels after intraperitoneal or intravenous 
injections. Such experiments were performed for the first time in our lab, both 
substances were chosen because they are frequently used in our projects. The aim of 
these studies was to determine suitable treatment regimes for our experiments with 
these compounds. We performed theoretical calculations on the expected blood 
concentration based on the assumption of a total amount of 1600µl blood per mouse, 
consisting of 800 µl serum and 800 µl cellular compounds. The blood concentration 
reached in our experiments was then compared to the expected value calculated 
before. For these experiments, the very common and widely used C57BL/6 mouse 
strain was chosen. These animals have a competent immune system and so they were 
suitable for such experiments due to creation of standard conditions. 
 
 
2.1. Archazolid A distribution 
 
To evaluate the concentration of archazolid A in murine serum after i.v. and i.p. 
injection, a C57BL/6 mouse model was chosen. Animals (n=8) were divided in two 
equal groups (n=4), mice in one of these groups received an intraperitoneal injection 
of 0.3 mg/kg archazolid A, while the other group received the same amount 
intravenously. Blood of two other mice was used for internal standards. After i.v. 
respectively i.p. treatment, blood was taken from one mouse each via heart punction 
at certain time points (0.5h, 1h, 2h, 6h) after the application, serum was separated of 
all probes afterwards. The evaluation of this experiment was performed by Dr. 
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Jennifer Herrmann (University of Saarland, Germany) using HPLC and mass 
spectrometry.  
Regarding the resulting graph, it is recognizable that the concentration of archazolid 
A increases directly after application, reaches its peak after 2h and lowers again 
afterwards in both forms of application (Figure 17 A), but the total concentration (in 
µM) in the serum was higher in probes of i.v. treated mice than in i.p. treated ones. 
Based on the dosage 0.3 mg/kg archazolid A meaning 0.6 µg/ 20 g mouse (standard 
mouse) and based on 800 µl serum per mouse, there should be 7.5 ng of archazolid A 
found in 1 µl serum. Interpretation is based on the following: Archazolid A holds a 
molecular weight of 737.98 g/mol. Using the formula n=m/M, we calculated that 
there should be 10 µM archazolid A in the total serum. In the experiment the highest 
reachable value with i.p. treatment lay at 4.0 µM and at 16.5 µM with i.v. treatment. 
(Figure 17 B) The concentration in the blood of archazolid A in i.p. treated animals 
did not reach the expected value of 10 µM while the values in the i.v. treated group 
exceeded 10 µM, this might be due to an impureness with polyethylene glycols of 
the i.v. probes which disturbed the measurements.  
 
 
Figure 17: Concentration of archazolid A in murine serum over time. A) Shown is the 
concentration (in µM) of archazolid A in murine serum 0h, 0.5h, 1h, 2h and 6h after intraperitoneal 
(i.p.) respectively intravenous (i.v.) injection. B) Shown are the exact values archazolid A reaches in 
the serum at certain time points after i.p. respectively i.v. application.  
 
 
2.2. Roscovitine distribution 
 
For this experiment, we also used a C57BL/6 mouse model. To evaluate the 
concentration in the blood of Cdk inhibitor roscovitine, blood was taken via heart 
punction from 18 C57BL/6 mice which were intraperitoneally treated with 
roscovitine (150 mg/kg). A blood take was performed at consecutive time points 
after application (10 min, 20 min, 30 min, 1h, 2h, 4h). We had to mix the blood of 
three mice per time point due to reduced blood exploitation after roscovitine 
treatment. Another three mice were just vehicle treated and used as internal standard. 
Blood was collected in EDTA coated sample tubes to prevent coagulation. The 
evaluation of the probes was carried out by Dr. Christoph Müller (University of 
Munich, Germany) performing HPLC and mass spectrometry.  
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The resulting graph shows an increasing blood concentration directly after injection 
which reaches its peak 30 min after i.p. application, from 30 min on, the roscovitine 
concentration lowers again. After 4h, the blood concentration seemed to reach a 
plateau. (Figure 18 A) We performed calculations on theoretical finding of 
roscovitine in the blood before. Based on the given dosage of 150 mg/kg roscovitine 
meaning 3 mg/ 20 g mouse (standard mouse) and based on 1600 µl blood per mouse, 
there should be 1.875 mg in 1 ml blood. 30 min after application, we were able to 
detect 178.1 µg in 100 µl blood equating 1.78 mg in 1 ml blood. (Figure 18 B) So, 
the detected value almost reaches the theoretical value. Therefore, we categorized i.p. 
injections as suitable and used them in our experiments with roscovitine. 
 
 
 
Figure 18: Distribution of roscovitine in murine blood over time. A) Shown is the concentration 
(in µg/ 100 µl blood) of roscovitine in blood 10 min, 20 min, 30 min, 1h, 2h and 4h after 
intraperitoneal injection. B) Shown are the exact values roscovitine reached in 100 µl blood at 
different time points during the experiment. 
 
 
3. Murine tumor models to evaluate the reduction of tumor growth through 
various compounds 
 
In this chapter different approaches were evaluated to hamper the growth of tumors 
through treatment with potential anti-cancer compounds. For this, different animal 
experimental setups were established. First, we analyzed the effect of V-ATPase 
inhibitor archazolid A on murine breast cancer cells (4T1-luc) in an allograft 
BALB/c nu/nu mouse model and afterwards its combinatorial properties together 
with cholesterol synthesis inhibitor simvastatin in a Scid mouse experiment and then 
the effect of its combination with the MDM2 inhibitor nutlin-3a in another 
experiment with BALB/c nu/nu mice. Furthermore, the roscovitine analogue LGR 
2674, PDI inhibitor PS89 and ACC inhibitor soraphen A were evaluated concerning 
their anti-cancer efficacy in Huh7 xenograft Scid mouse experiments. 
Therapy started when all or most of the mice beared a tumor, end points were chosen 
due to the mice‘ general condition and due to tumor’s size, a critical mark of 1000 
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mm
3
 should not be exceeded to prevent mice from pain and limitations in their 
physiological course of motions. 
 
 
3.1. Evaluation of the effect of archazolid A treatment on murine breast cancer 
in an allograft tumor experiment 
 
Due to a project in our lab where the potential of archazolid A to initiate apoptosis of 
cancer cells as a consequence of disturbed iron metabolism was focused [124], we 
evaluated the influence of this V-ATPase inhibitor on tumor growth of murine breast 
cancer tumors. A murine allograft tumor model, using eight BALB/c nu/nu mice, 
was chosen. 4T1 cells originate from BALB/c mice, a strain which is similar to the 
chosen BALB/c nu/nu mouse model. Mice were divided into two groups (n=4) and 
received 1 x 10
6
 murine breast cancer cells (4T1-luc). Tumor bearing mice were 
daily and intraperitoneally treated either with archazolid A (0.3 mg/kg) or vehicle 
seven times altogether, starting on day six after tumor cell inoculation.  
Treatment with archazolid A lowered tumor volume over time compared to the 
control group. On day 11, tumor volume in the archazolid A treated group was 
significantly lower in comparison to control. (Figure 19 A) Tumor volumes were 
measured last on day 12 while on final day of the experiment (d13) tumors were 
resected and weighed. Weighing of tumors after resection led to no significant 
differences between both groups. (Figure 19 B) 
 
Figure 19: Tumor growth over time and tumor weight after resection. A) Development of tumor 
volume over time, group with daily archazolid A (0.3 mg/kg) treatment compared to vehicle treated 
control group. Represented is the mean ± S.E.M. of four mice per group. Statistical analyses were 
performed using t-test (* p< 0.05, ** p< 0.01). B) Comparison of tumor weight in both groups after 
tumor resection (d13). Represented is the mean ± S.E.M. of four mice per group. Statistical analyses 
were performed using t-test (n.s. = not significant).  
 
All mice showed an unchanged general condition during the whole experiment, both 
groups did not show non physiological variations in weight. (Figure 20) 
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Figure 20: Weight over time. Development of mice‘ weight during the experiment, measured three 
times, starting with injection of cells (day 0) and ending with euthanasia (day 13). Represented is the 
mean ± S.E.M. of four mice per group. 
 
  
3.2. Examination of combinatorial effects of simvastatin and archazolid A on 
HCC using a xenograft model  
 
This experiment was performed due to an in vitro project where the focus was laid on 
the effects of archazolid A on cholesterol metabolism in cancer cells. The aim of this 
experiment was to evaluate the effect on hampering tumor growth in vivo using the 
established cholesterol synthesis inhibitor simvastatin and our natural compound 
archazolid A, on the one hand in single use and on the other hand in combination. A 
Scid mouse xenograft model with 32 animals was chosen to evaluate this. The in 
vitro experiments were performed with Huh7 cells and led to promising results, so 
we chose this cell line for the in vivo experiment, too. Scid mice are T-cell and B-
cell deficient and the human Huh7 cell line grows very fast and very reliable in this 
strain. Mice were divided into four groups (n=8), one group was treated with solvent 
as a control, one group was treated with simvastatin (10 mg/kg), one group was 
treated with archazolid A (0.2 mg/kg) and one group was treated with a combination 
of both. 3 x 10
6
 hepatocellular carcinoma cells (Huh7) were injected (day 0), daily 
therapy of tumor bearing mice started on day 7 after cell inoculation und lasted until 
day 17.  
One mouse of the control group and two mice in the simvastatin treated group did 
not develop any tumor over time. The tumor volume in the archazolid A treated 
group was significantly lower compared to control group in the last two 
measurements of the experiment, d15 (Figure 21 C) and d17 (Figure 21 D). Single 
simvastatin treatment and combinatorial treatment with archazolid A led to no 
significant differences in tumor volume compared to the control group. (Figure 21 A) 
On final day of experiment (d17) mice were sacrificed through cervical dislocation, 
after that all tumors were resected and weighed. The weight of tumors showed no 
significant differences between the groups. Simvastatin treated mice developed the 
most heavy tumors while the archazolid treated ones developed the lightest tumors. 
(Figure 21 B) 
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Figure 22 shows that mice in all groups kept a healthy general condition and showed 
just physiological fluctuations in weight over the whole experimental period.  
 
Figure 21: Tumor volume and weight during experimental period. A) The graph shows the 
average tumor volume of each group, control, simvastatin (10 mg/kg) treated, archazolid A (0.2 
mg/kg) treated and combinatorial treatment. On day 15 and day 17 the archazolid A treated group 
showed a significantly lowered tumor volume compared to the control. Represented is the mean ± 
S.E.M. per group. Differences were evaluated with One-way ANOVA test (* p< 0.05, ** p< 0.01). B) 
Tumor weight after resection (day 17) in all groups. Represented is the mean ± S.E.M. per group. 
Differences were evaluated via One-way ANOVA test (n.s.). C) Shown is the tumor volume of all 
groups on day 15 of the experiment. Tumor volume in single archazolid A treated group was 
significantly lowered compared to control. Represented is the mean ± S.E.M. per group. Differences 
were evaluated with One-way ANOVA test (* p< 0.05, ** p< 0.01). D) Shown is the tumor volume of 
all groups on day 17 of the experiment. Tumor volume in single archazolid A treated group was 
significantly lowered compared to control. Represented is the mean ± S.E.M. per group. Differences 
were evaluated with One-way ANOVA test (* p< 0.05, ** p< 0.01). 
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Figure 22: Weight development over time. Weight of mice during experimental period was assessed 
on day 0, day 7 and day 15 and is shown for all four groups. Represented is the mean ± S.E.M. per 
group. 
 
 
3.3. Effects of combinatorial treatment of nutlin-3a and archazolid A on 
glioblastomas shown in a xenograft tumor model  
 
This in vivo experiment contributed to a project of our lab where we showed that the 
inhibition of V-ATPases influences p53 levels positively in vitro. So, we analyzed 
the single and combinatorial effect of p53 activator nutlin-3a and V-ATPase inhibitor 
archazolid A in a xenograft model using BALB/c nu/nu mice and glioblastoma cells. 
The T-cell deficient BALB/c nu/nu strain was chosen according to its good growth 
properties for this human cell line. 32 BALB/c nu/nu mice got an injection of 5 x 10
6
 
U87MG cells into the left flank and were divided into four groups (n=8) afterwards. 
Tumor bearing mice were daily intraperitoneally treated either with solvent, with 0.2 
mg/kg archazolid A, with 5 mg/kg nutlin-3a or with a combination of both. Therapy 
started on day seven after cell application and lasted until day 25. Two mice in the 
control group, one mouse in the archazolid A treated group and one mouse in the 
nutlin-3a group died during the experiment.   
The evaluation of the experiment was realised by jun.- Prof. Thorsten Lehr 
(University of Saarland, Germany) through specific modeling (description in 2.2.4.6. 
of this thesis). In Figure 23 A the tumor growth over time is shown. Growth rate of 
tumors treated with combination was significantly reduced compared to control. 
Moreover, the combination of archazolid A and nutlin-3a was most effective in 
reducing tumor volume (50.4%). (Figure 23 B)  
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Figure 23: Tumor volume and growth rate. A) Shown is the tumor growth curve over time of four 
groups, one treated with solvent (control), one treated with archazolid A (0.2 mg/kg), one treated with 
nutlin-3a (5 mg/kg) and one treated with a combination (0.2 mg/kg archazolid A and 5 mg/kg nutlin-
3a). Represented is the mean ± S.D. per group. B) Shown is the growth rate (h
-1
) and the reduction of 
tumor volume (%) in all four groups. 
 
Surviving mice kept a proper general condition during the experimental period and 
gained weight. (Figure 24) 
 
 
Figure 24: Weight development over time. Surviving mice kept their weight during experimental 
period. Starting with tumor cell application (day 0) ending with euthanasia (day 25). Weight was 
assessed four times (d0, d8, d14, d19). Represented is the mean ± S.E.M. per group.  
 
 
3.4. Effect of LGR 2674 on HCC tumors evaluated in a xenograft model 
 
LGR 2674, an analogue of the established Cdk inhibitor roscovitine, was evaluated 
in vivo for the very first time. According to promising in vitro results concerning the 
inhibition of Huh7 proliferation in one of our current projects [68], it should be 
evaluated in vivo. Its effect on tumor growth was evaluated in a Huh7 xenograft 
model. Scid mice were chosen according to prior experiments where the cells grew 
very good in this strain and formed tumors very fast. 3 x 10
6
 tumor cells were 
injected. Mice were divided into two groups (n=10). With appearing of tumors on 
day eight after cell application, daily treatment with LGR 2674 (1.5 mg/kg) started in 
one group, the other one received a daily intraperitoneal injection of solvent. The 
experiment lasted until day 20 after cell inoculation. 
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One mouse in the control group did not develop any tumor at all. One mouse of the 
control group and one mouse of the LGR 2674 treated group had to be taken out of 
the experiment on day 17, because their tumor volume reached the critical mark of 
1000 mm
3
. Comparison of tumor volume in the control group and in the  LGR 2674 
treatment group showed that intraperitoneal therapy of Scid mice with LGR 2674 
significantly reduced the volume of tumors on day 17. (Figure 25 A) The resection of 
the tumors after euthanasia showed no significant reduction of tumor weight in LGR 
2674 treated mice compared to the control group. (Figure 25 B) 
 
Figure 25: Development of tumors over time and weight after resection. A) Shown is the growth 
of Huh7 tumors during the whole experimental period until day 20 in both groups, control and LGR 
2674 (1.5 mg/kg) treated. Represented is the mean ± S.E.M. per group. Differences were evaluated 
with t-test (* p< 0.05, ** p< 0.01). B) Tumors were weighed on day 20 and both groups were 
compared. Represented is the mean ± S.E.M. per group. Differences were evaluated with t-test (n.s.).  
 
 
Control mice showed a healthy general condition over the whole experimental 
period, in contrast to that, mice in the LGR 2674 group lost weight with beginning of 
treatment on day eight (Figure 26). On day 19, one mouse in the LGR 2674 treatment 
group was found dead in the cage. Mice in this therapy group showed signs of 
reduced general condition, e.g. fur clotted with feces around the anus, horrent fur and 
reduced activity. 
 
Figure 26: Weight of mice over time. Shown is the constant weight of mice in the control group and 
weight loss of mice in the LGR 2674 treated group during the experimental period. Weight was 
assessed four times at all, starting with tumor cell injection (day 0) and ending with euthanasia (day 
20). Represented is the mean ± S.E.M. per group. 
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3.5. Effect of PS89 in combination with sorafenib on HCC tumors shown in a 
xenograft model 
 
Sorafenib is an established therapeutic agent in HCC treatment, but resistances occur 
more and more. So, we wanted to analyze if the new PDI inhibitor PS89 would have 
a sensitizing effect on tumor cells for sorafenib treatment to hamper tumor growth. 
For this experiment a xenograft model using Scid mice, which are very suitable for 
Huh7 models, was chosen. We injected 3 x 10
6
 Huh7 cells subcutaneously in 32 Scid 
mice. These animals were divided into four groups (n=8), control, single PS89 (20 
mg/kg) treated, single sorafenib (10 mg/kg) treated and combinatorial treated. Mice 
were intraperitoneally treated three times a week, therapy started on day 10 after cell 
inoculation and lasted until day 19 ending with euthanasia. 
One mouse in each group and two mice in the control group did not develop any 
tumor over the whole experimental period at all. Tumor development over time 
showed an almost equal volume in all of the groups, there was no significant 
difference in tumor volume between them. (Figure 27 A-B) The experiment was 
ended on day 19 with euthanasia because tumors reached the 1000 mm
3
 mark. 
Results of weighing of tumors showed that the lightest tumors are developed by mice 
of the control group, while tumors of mice in PS89, sorafenib and combinatorial 
group showed a higher and almost equal weight. So, there were no significant 
differences in tumor weight. (Figure 27 C) Mice kept a healthy general condition 
during the experiment and weight loss and gain are fluctuating in a physiological 
range. (Figure 27 D) 
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Figure 27: Tumor development over time and weight of mice. A) Shown is tumor volume over 
time of Scid mice bearing subcutaneous tumors in a control group, a sorafenib (10 mg/kg) treated 
group, a PS89 (20 mg/kg) treated group and a combinatorial treatment group. Represented is the mean 
± S.E.M. per group. Differences were evaluated with One-way ANOVA test (n.s.). B) Shown is tumor 
volume of all groups on final day of experiment (day 19). Represented is the mean ± S.E.M. per 
group. Differences were evaluated with One-way ANOVA test (n.s.). C) Weight of tumors on final 
day of the experiment (day 19) is shown. Represented is the mean ± S.E.M. per group. Differences 
were evaluated with One-way ANOVA test (n.s.). D) Weight of mice during the whole period of the 
experiment, starting with tumor cell inoculation (day 0) and ending with euthanasia (day 19). 
Measurements performed on day 0, day 9 and day 16. Represented is the mean ± S.E.M. per group. 
 
 
3.6. Use of a xenograft tumor model to evaluate the effect of soraphen A on 
HCC tumors 
 
Within a soraphen A project of our lab, we wanted to evaluate the efficacy of the 
natural compound soraphen A on hampering tumor growth. So, a xenograft tumor 
model was chosen. Such an experiment was performed for the first time with this 
experimental drug, it corresponds with an in vitro project performed in our lab, 
where soraphen A inhibited the proliferation of Huh7 cells in cell culture. That is 
why Huh7 cells were chosen for this animal experiment. Scid mice are suitable for 
this human tumor cell line. 3 x 10
6
 hepatocellular carcinoma cells (Huh7) were 
subcutaneously injected into Scid mice. Tumor bearing mice were separated into two 
groups (n = 10), two mice in the soraphen A treated group did not develop any tumor 
over time. One group was treated with solvent and the other group was treated with 
soraphen A (40 mg/kg). Daily therapy started on day seven after tumor cell 
application and mice received therapy for nine times altogether. Treatment with 
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soraphen A mediated a lower tumor size compared to the control group, volume of 
tumors in the soraphen A treated group was significantly lower compared to control 
group on the last three days of the experiment (d14, d15 and d16). (Figure 28 A) On 
day 16 all mice were euthanised, the comparison of tumor weight of both groups 
after resection showed no significant difference between soraphen A treated mice 
compared to control. (Figure 28 B).  
 
Figure 28: Tumor volume and weight A) Shown is the growth of Huh7 tumors over time in both 
groups, control and soraphen A (40 mg/kg) treated. Represented is the mean ± S.E.M. per group. 
Results are statistically evaluated with t-test (* p< 0.05, ** p< 0.01 B) Shown is tumor weight after 
resection out of the body on day 16. Represented is the mean ± S.E.M. per group. Results are 
statistically evaluated with t-test (n.s.). 
 
Figure 29 shows that all mice kept a healthy general condition and that the weight 
loss and gain fluctuated in a physiological range. 
 
Figure 29: Weight over time: Mice did hardly lose weight during experimental period. Weight was 
assessed four times (d0, d5, d12, d16). Represented is the mean ± S.E.M. per group. 
 
 
4. Murine tumor models to evaluate tumor dissemination 
 
In this kind of experiments, the aim was to evaluate the dissemination of tumor cells 
after i.v. injection. Three different methods were established with a variety of 
different experimental setups. For all of them, luciferase tagged cells (4T1-luc and 
Jurkat-luc) were used which made it possible for us to detect the distribution of 
tumor cells in the body of living mice with our bioluminescence in vivo imaging 
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system (IVIS®). We evaluated the distribution of human leukemia cells (Jurkat-luc) 
in three different murine models (Scid, Nod-Scid and NSG mice) without any 
treatment to find out in which model the cells were able to disseminate at all and to 
establish a suitable mouse model for a leukemia project. The effects of soraphen A 
treatment and likewise tetrandrine treatment on murine breast cancer cells (4T1-luc) 
were evaluated both in allograft tumor models using BALB/c mice, because 4T1 
cells originate from this strain. 
 
 
4.1. Evaluation of suitable mouse models for a leukemia project 
 
Concerning a leukemia project in our lab, Jurkat-luc cells should be tested in vivo. 
Due to the fact that there exist, to our knowledge, no published data on the most 
suitable mouse strain for leukemia models in general, this experiment was performed 
with three different strains. We used three Scid mice, three Nod-Scid mice and three 
Nod-Scid-Gamma (NSG) mice. Each of these animals received 1 x 10
6
 Jurkat-luc 
leukemia cells via injection into the tail vein. Bioluminescence imaging started on 
day four after cell inoculation with the Scid and Nod-Scid animals and on day two 
with NSG mice, all Scid and Nod Scid mice lay in ventrodorsal position during the 
procedure, the NSG mice in ventrodorsal and dorsoventral positions.  
The bioluminescence signals the imager detected are represented in Figure 30 A-B, 
always one picture out of the sequence was chosen. Scid and Nod Scid mice were 
imaged six times altogether (d4, d7, d11, d13, d19, d21), no bioluminescence signals 
equating tumor cell dissemination were detectable. Mice were euthanised on day 21. 
NSG mice were imaged nine times altogether (d2, d5, d8, d12, d15, d19, d22, d26, 
d29), the first bioluminescence signals were detected on day five after cell 
inoculation. The first one was remarkable in dorsoventral position in the region of 
the tail base in one mouse. Three days later, we noticed a daily increase of the signal 
and from day 15 on, all three mice showed a strong bioluminescence signal in 
different parts of the body in both imaging positions. We continued the imaging 
process until day 29 after cell application, strong bioluminescence signals were 
presented in ventrodorsal positions as well as in dorsoventral positions. Concerning 
mice‘ anatomy, the strongest signals detected at dorsoventral imaging positions came 
from medulla and brain and from lungs, heart, liver, stomach, femurs and bladder, 
imaged in ventrodorsal positions. After the last procedure on day 29, all mice were 
sacrificed.  
During the trial, all mice were in a healthy general condition and did not show any 
weight loss (Figure 31). 
The consequence of this experiment was that just NSG mice can be used in 
bioluminescence imaging experiments with Jurkat-luc cells and other leukemia 
models. 
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Figure 30: Bioluminescence images. A) Pictures of tumor burden in NSG mice until day 29 after 
Jurkat-luc cell inoculation, taken on day 2, 5, 8, 12, 15, 19, 22, 26, 29, in ventrodorsal (dv) and 
dorsoventral (dv) imaging positions. B) Ventrodorsal bioluminescence pictures of Scid and Nod Scid 
mice taken on day 4, 7, 11, 13, 19 and 21 after cell application. 
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Figure 31: Weight over time. Weight of Scid and Nod-Scid mice over time, starting with tumor cell 
injection (day 0), ending with euthanasia (day 21). And weight of NSG mice starting with tumor cell 
injection (day 0) and ending with euthanasia (day 29). Weight was assessed on day 0, 4, 11, 19, 21 
and 29 (d29 just for NSG mice). Represented is mean ± S.E.M. of three mice per group. 
 
 
4.2. Murine tumor models to evaluate the effect of tetrandrine on tumor 
dissemination 
 
The in vivo dissemination of 4T1-luc cells under tetrandrine treatment was evaluated 
in three different setups due to a project in which the inhibition of two-pore channels 
through tetrandrine was focused. 
 
In our first experiment, 20 BALB/c mice were separated into two groups (n=10), 
each mouse received 1 x 10
5
 4T1-luc cells via i.v. injection. One group was treated 
with solvent as a control, the other one was treated with tetrandrine in a dosage of 
100 mg/kg. Solvent respectively tetrandrine were intraperitoneally administered 24 
hours and 4 hours before cell application and a third time 24 hours after it. On day 
eight after inoculation of cells, both groups were imaged with the IVIS® Spectrum in 
ventrodorsal imaging positions. One mouse of the control group died during the 
experiment.  
Figure 32 represents the bioluminescence signal equating the tumor burden in the 
lungs on day eight after cell application. For evaluation, regions of interest (ROIs) 
were defined and the total signal per ROI was calculated as photons/second/cm
2
 
(total flux/area). The tumor burden in the lungs of the tetrandrine treated group was 
significantly higher compared to the control group, which was a controversial result 
for us.  
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Figure 32: Average tumor burden in the lungs on day 8. A) The average bioluminescence signal of 
both groups is shown in ventrodorsal imaging positions. Represented are nine mice in the control and 
ten mice in the tetrandrine (TET) treated group. B) Regions of interest (ROIs) were defined and the 
total signal per ROI was calculated as photons/second/cm
2
 (total flux/area). Represented is the mean ± 
S.E.M. of nine/ten mice per group. Significance of the results was evaluated using t-test (* p< 0.05, ** 
p< 0.01). 
 
The animals showed no changes in their general condition and did not lose weight 
during the experimental period which was ended on day eight. (Figure 33) 
 
 
Figure 33: Weight over time. Shown is the weight development over eight days during the 
experiment, measured on day 0 and day 8. Represented is the mean ± S.E.M. of nine/ten mice per 
group. 
 
 
Subsequently, it was clear that this experimental setup was not suitable for such a 
dissemination experiment with tetrandrine. So, we established another setup within 
this trial. 24 BALB/c mice were divided into three groups (n=8), one group received 
with DMSO pre-treated 4T1-luc cells and was treated itself with solvent three times, 
another group also received with DMSO pre-treated 4T1-luc cells and was treated 
itself with tetrandrine (100 mg/kg solved in HCl) three times, and another group 
received cells, pre-treated with tetrandrine (10 µM, 24h) and received just one 
treatment of tetrandrine (100 mg/kg) directly after cell injection. All animals passed 
through bioluminescence imaging on day eight after injection of cells. Each of them, 
except of one mouse in the three times tetrandrine treated group exhibited a thoracic 
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luminescent signal reflecting the tumor burden in the lungs. All bioluminescence 
images were quantified by defining ROIs and then calculating the total signal per 
ROI as total flux/area. Figure 34 shows that the bioluminescence signal of control 
mice lay at 2.5 x 10
8
, while the group with three time tetrandrine treatment (TET) lay 
at 7.5 x 10
8
 and the group with pre-treated cells and one time tetrandrine treatment 
lay at 2 x 10
9
. Mice which received pre-treated cells plus one tetrandrine therapy 
showed a significant higher bioluminescence signal compared to the control group, 
which actually was expected to be the group with the highest signal.  
 
 
Figure 34: Average tumor burden in the lungs on day 8. A) The average bioluminescence signal of 
all groups is shown in ventrodorsal pictures, one group is consisting of eight mice. B) Regions of 
interest (ROIs) were defined and the total signal per ROI was calculated as photons/second/cm
2
 (total 
flux/area). Represented is the mean ± S.E.M. of eight mice per group. Significance of the results was 
evaluated using One-Way ANOVA test (* p< 0.05, ** p< 0.01). 
 
The experiment was ended after imaging on day eight with euthanasia, all mice 
showed a proper general condition concerning their body weight during the 
experiment, although variabilities occurred. (Figure 35) But, some of the mice 
showed small wounds at the points of intraperitoneal injections, referable to HCl 
used as solvent. Mice with the highest tumor burden also showed the most weight 
loss. 
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Figure 35: Development of mice‘ weight over time. Weight of all groups is shown from cell 
injection (day 0), over day 4 until euthanasia (day 8). Represented is the mean ± S.E.M. of eight mice 
per group.   
 
 
Due to these controversial results, the experimental setup had to be totally changed. 
So, another experimental setup was established within two groups of BALB/c mice, 
each group consisting of eight mice. One group received 1 x 10
5
 with DMSO pre-
treated 4T1-luc cells i.v. while the other one received 1 x 10
5
 tetrandrine pre-treated 
cells (10 µM, 24h) intravenously injected. Bioluminescence imaging was performed 
five and seven days after cell application. All mice, except one in the tetrandrine 
group, showed a thoracic bioluminescent signal. Ventrodorsal images show the 
tumor burden in the lungs. The signal was calculated as total flux/area after defining 
ROIs. On day five, the group with tetrandrine pre-treated cells showed a significantly 
lower bioluminescence signal, equivalent to tumor burden, compared to the control 
group. (Figure 36) The result of day eight was not significant concerning the 
difference between both groups. (Figure 37) During the whole experimental period, 
all mice showed a good general health condition and even gained weight. (Figure 38) 
 
 
 
Figure 36: Day 5, average tumor burden in the lungs. A) The average bioluminescence signal of 
both groups is shown in ventrodorsal pictures. B) Regions of interest (ROIs) were defined and the 
total signal per ROI was calculated as photons/second/cm
2
 (total flux/area). Represented is the mean ± 
S.E.M. of eight mice per group. Significance of the results was evaluated with t-test (* p< 0.05, ** p< 
0.01). 
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Figure 37: Day 8, average tumor burden in the lungs. A) The average bioluminescence signal of 
both groups is shown in ventrodorsal pictures. B) Regions of interest (ROIs) were defined and the 
total signal per ROI was calculated as photons/second/cm
2
 (total flux/area). Represented is the mean ± 
S.E.M. of eight mice per group. Significance of the results was evaluated with t-test (* p< 0.05, ** p< 
0.01). 
 
 
Figure 38: Weight over time diagram. Weight development of mice in both groups over 
experimental period, measured on day 0 and day 8. Represented is the mean ± S.E.M. of eight mice 
per group. 
 
 
4.3. Using an allograft tumor model to evaluate the effect of soraphen A on 
tumor dissemination 
 
Within a soraphen A project, we decided to use BALB/c mice for this allograft tumor 
experiment because they are syngeneic with the 4T1-luc cells we wanted to use. For 
the evaluation of the effect of ACC inhibitor soraphen A concerning the 
dissemination of murine breast cancer cells (4T1-luc) after i.v. injection into BALB/c 
mice, we compared mice which received soraphen A pretreated cells in two different 
concentrations with control mice which received vehicle pre-treated cells. Animals 
were divided into three groups (n=8), the control group received 1 x 10
5
 vehicle pre-
treated 4T1-luc cells via i.v. injection, the second group received cells which were 
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pre-treated with 1µM soraphen A for six hours and the third group received cells 
with a soraphen A pre-treatment of 25 nM over 72 hours. All mice passed through a 
bioluminescence imaging on day four and day seven after tumor cell inoculation, 
mice were imaged in ventrodorsal positions. On day seven all mice were euthanised. 
Seven out of eight mice in the control group showed a very strong bioluminescence 
signal on day four, three days later, all of the mice in the control group showed a firm 
signal. All animals in the six hours pre-treated as well as in the 72 hours pre-treated 
group evinced bioluminescence signals on day four and seven, whose total flux/area 
rates equating tumor burden in the lungs were lower compared to the burden in the 
control group. (Figure 39 A) Mice which received cells with soraphen A treatment 
over 72h showed a significantly reduced tumor burden compared to the control group 
on day four and day seven. (Figure 39 B) 
 
 
Figure 39: Dissemination of tumor cells in the body. A) Bioluminescence signals in the lungs in 
ventrodorsal imaging positions on day four and day seven after cell inoculation, three groups (n=8) 
are shown, one with vehicle pre-treated cells, one with soraphen A (1 µM) pre-treatment over 6h  and 
one with soraphen A (25 nM) pre-treatment over 72h. B) Regions of interest (ROIs) were defined and 
the total signal per ROI was calculated as photons/second/cm
2
 (total flux/area), results of day 4.  
Represented is the mean ± S.E.M. of eight mice per group. Significance of the results was evaluated 
using One-way ANOVA test (* p< 0.05, ** p< 0.01). C) Regions of interest (ROIs) were defined and 
the total signal per ROI was calculated as photons/second/cm
2
 (total flux/area), results of day 7. 
Represented is the mean ± S.E.M. of eight mice per group. Significance of the results was evaluated 
using One-way ANOVA test (* p< 0.05, ** p< 0.01). 
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All mice gained weight during the whole experimental period and stayed in a good 
general condition. (Figure 40) 
 
Figure 40: Weight over time. Weight development of mice in all groups, starting with i.v. injection 
of cells (day 0) until euthanasia (day 7). Represented is the mean S.E.M. of eight mice per group over 
time.  
 
 
5. Murine tumor experiments to show the influences of Cdk5 on tumor 
development 
 
The focus of this chapter lies on the establishment of in vivo experiments usable for 
the evaluation of the influences which the cyclin-dependent kinase 5 has on tumor 
development. We performed different experiments. We used a Cdk5 knock-down in 
Huh7 cells and treated the mice with the HCC therapeutic sorafenib, furthermore we 
used C57BL/6 mice with an inducible endothelial Cdk5 knock-out in combination 
with the Cdk inhibitor roscovitine. In addition, two murine limiting dilution 
experiments were performed, T24 Cdk5 knock-down cells as well as 4T1-luc cells in 
combination with Cdk5 inhibitor dinaciclib were used. Both trials were performed to 
evaluate the influence of cancer stem cells on tumor development and growth.   
 
 
5.1. Evaluation of the effect of a Cdk5 knock-down in Huh7 cells in combination 
with sorafenib treatment in a xenograft model 
 
The aim was the realisation of an in vivo experiment due to a current HCC project in 
our lab. To evaluate the effect of Cdk5 in HCC tumor development, 24 BALB/c mice 
received either Huh7 nt shRNA (n=12) or Huh7 cells with a Cdk5 knock-down 
(Huh7 Cdk5 shRNA) (n=12). After tumors arose, each group was divided a second 
time into a part which was vehicle treated and a part which was treated with the 
established HCC therapeutic sorafenib (10 mg/kg). Daily intraperitoneal therapy for 
tumor bearing mice started on day 11 after cell application and lasted until day 18, 
tumor volume was measured every second day. All groups, Huh7 nt shRNA cells 
receiving solvent treatment (n=5, because one mouse did not develop any tumor), 
Huh7 nt shRNA cells receiving sorafenib treatment (n=6), Huh7 Cdk5 shRNA cells 
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receiving solvent (n= 6) and Huh7 Cdk5 shRNA receiving sorafenib treatment, were 
compared to each other.  
The Cdk5 knock-down in Huh7 cells seemed to sensitize HCC tumors to sorafenib 
treatment in vivo, because the combination of Cdk5 knock-down and sorafenib 
treatment led to the lowest tumor volume. Differences are not significant. (Figure 41 
A-C) All mice were in a good general condition and showed constant body weight. 
(Figure 41 D) 
 
Figure 41: Tumor development and weight of mice  A) Tumor development over time, four groups 
are shown, one with Huh7 nt cells and solvent treatment (n= 5), another with Huh7 nt cells and 
sorafenib treatment (10 mg/kg) (n=6), the third and fourth one with Huh7 Cdk5 shRNA cells and 
either solvent (n=6) or sorafenib (n=6) treatment. Shown is the development of tumors over time, 
starting with s.c. injection of cells (day 0) until euthanasia (day 18). Represented is the mean ± S.E.M. 
per group. Results were statistically evaluated with One-way ANOVA test (n.s.). B) Shown is the 
tumor volume of all four groups on final day of experiment (d18). Represented is the mean ± S.E.M. 
per group. Results are statistically evaluated via One-way ANOVA test (n.s.). C) Weight of tumors 
after resection. Shown is the weight of tumors on day 18 of experiment after resection from the body. 
Represented is the mean ± S.E.M. of five respectively six mice per group. Results are statistically 
evaluated with One-way ANOVA test (n.s.). D) Weight of mice over time. Shown is the weight of 
mice in all of the four groups during the whole experimental period. Starting with injection of tumor 
cells (d0) until euthanasia (d18). Weight was assessed three times (d0, d7, d18). Represented is the 
mean ± S.E.M. of five respectively six mice per group. 
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5.2. Effect of an inducible endothelial Cdk5 knock-out in mice in combination 
with roscovitine on melanoma tumors 
 
Concerning a revision of a submitted manuscript focused on the reduction of tumor 
growth through the inhibition of endothelial Cdk5, we wanted to evaluate the effects 
of an inducible endothelial Cdk5 knock-out in mice in combination with roscovitine 
treatment on tumor growth of B16F1 cells. 6 C57BL/6 mice with Cdk5 knock-out 
(Cdk5 
fl/fl
 VECCre+) were used for that. Mice were provided by Dr. Johanna Liebl 
(University of Munich, Germany). All mice received a subcutaneous injection of 1 x 
10
6
 B16F1 cells (murine melanoma cells) into the left flank (d0). When first tumors 
were visible and palpable (day 7), mice received either solvent or roscovitine (150 
mg/kg) treatment three times a week, experiment was ended on day 14 after cell 
application. So, mice received therapy for four times (d7, d9, d11, d14). In Figure 42 
is shown that Cdk5 knock-out mice receiving solvent (n=3) developed a higher 
tumor volume compared to Cdk5 knock-out mice receiving roscovitine (n=3). 
Differences between the groups were not significant. So, an endothelial Cdk5 knock-
out sensitizes tumors for chemotherapy. 
Mice were euthanised on day 14 after cell application, after resection, all tumors 
were weighed. Control group of Cdk5 knock-out mice developed heavier tumors 
then the roscovitine treated ones did. (Figure 42 C) During the whole experimental 
period, all mice kept a healthy general condition and they gained weight. (Figure 42 
D) 
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Figure 42: Tumor volume and weight of mice. A) Shown is the average tumor volume over the 
experimental period. Listed are mice with an inducible endothelial Cdk5 knock-out (Cdk5 
fl/fl
 
VECCre+), treated either with solvent or with roscovitine (150 mg/kg) (n=3 in each group). Therapy 
started on day seven after tumor cell application. Represented is the mean ± S.E.M. of 3 mice per 
group. Results are statistically evaluated with t-test (n.s.). B) Shown is tumor volume of all groups on 
final day of experiment (d14). Represented is the mean ± S.E.M. of 3 mice per group. Results are 
statistically evaluated with t-test (n.s.). C) Tumor weight on final day of experiment. Shown is tumor 
weight after resection on last day of experiment (day 14). Cdk5 knock-out mice were used. 
Represented is the mean ± S.E.M. of 3 mice per group. Results are statistically evaluated with t-test 
(n.s.). D). Weight was assessed on day 0, day 7 and day 14. All mice gained weight during the 
experimental period. Represented is the mean ± S.E.M. of 3 mice per group. 
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5.3. Limiting dilution experiment with T24 cells 
 
The limiting dilution assay is applied to evaluate the tumor initiating potential of 
CSCs. So, to evaluate the influence of tumor initiating cells and their importance for 
tumor development and growth in combination with Cdk5 inhibition, a murine 
xenograft limiting dilution experiment was performed. T24 nt shRNA and T24 Cdk5 
shRNA cells in different amounts were injected into BALB/c nu/nu mice 
subcutaneously into the left flank of the mice. Tumors were measured three times a 
week and so the tumor volume was evaluated, experiment lasted over 42 days, 
measurements started seven days after cell application when first tumors arise. 
Evaluated were 5 x 10
6
, 2.5 x 10
6
, 1 x 10
6
, 5 x 10
5
 and 1 x 10
5
 of each cell type, aside 
from the amount 5 x 10
6
, all other cell numbers were evaluated in pairs (2.5 x 10
6
 
and 1 x 10
5
;  1 x 10
6
 and 5 x 10
5
), the higher one injected into the left flank of a 
mouse and the lower one injected into the right flank of the same mouse.  
All in all, tumors arosen of T25 Cdk5 shRNA cells showed a higher volume during 
the experiment and on final day (d42) compared to tumors arosen of T24 nt shRNA 
cells (Figure 43 A-B), while the start of growing and the number of tumors that arose 
varied totally between the groups. (Figure 43 C) Numbers of tumors that arose are 
equal in all groups (n=5), except from 1 x 10
5
 where 3 respectively 4 tumors arose. 
(Figure 43 C) 
Weighing after the resection of all tumors also showed that those tumors arosen of 
T24 Cdk5 shRNA cells not only developed the higher tumor volume but also the 
higher tumor weight. (Figure 43 D) These results were not significant. 
It is also noticeable, that in the T24 Cdk5 shRNA cell type the amount of 1 x 10
6
 
injected cells lead to the highest tumor volume and the highest tumor weight. So, 1 x 
10
6
 might be the best amount of cells for injection in tumor growth experiments with 
B16F1 cells. 
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Figure 43: Tumor development and weight. T24 nt shRNA as well as T24 Cdk5 shRNA cells were 
subcutaneously injected into BALB/c nu/nu mice. We used five cell amounts of each cell line. Seven 
days after application, mice started to bear tumors, experiment lasted until day 42 after application and 
ended with euthanasia. A) Shown is the development of tumors of all cell amounts over time. Mice 
received either 5 x 10
6
, 2.5 x 10
6
, 1 x 10
6
, 5 x 10
5
 or 1 x 10
5
 cells (T25 nt shRNA or T24 Cdk5 
shRNA). Represented is the mean ± S.E.M. of five mice per group. Results are statistically evaluated 
with One-way ANOVA test (n.s.). B) Shown is the tumor volume on final day of experiment (d42). 
Represented is the mean ± S.E.M. of five mice per group. Results are statistically evaluated with One-
way ANOVA test (n.s.). C) Total amount of arosen tumors. Shown is a list of the accruement of 
tumors in days after the inoculation and the number of tumors developed until d42.  D) Weight of 
tumors after resection. Shown is the tumor weight on final day of experiment (d42). Represented is 
the mean ± S.E.M. of five mice per group. Results are statistically evaluated with One-way ANOVA 
test (n.s.). 
 
All mice kept a good general condition during the whole experimental period and 
gained weight. (Figure 44) They were sacrificed through cervical dislocation on day 
42.  
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Figure 44: Weight of mice during experiment. Shown is the development of mice‘ weight during 
the whole experimental period. Starting with cell injection (d0) ending with euthanasia (d42). Shown 
is the group of mice receiving 5 x 10
6
 cells (left flank),  2.5 x 10
6
 and 1 x 10
5 
cells (left and right 
flank) and  1 x 10
6
 and 5 x 10
5 
(left and right flank), these three groups for each cell type. Represented 
is the mean ± S.E.M. of five mice per group. 
 
 
5.4. Limiting dilution experiment with 4T1-luc cells 
 
For the evaluation of tumor initiating cells in 4T1-luc tumors in combination with 
Cdk5 inhibition through dinaciclib, a murine allograft limiting dilution experiment 
was performed. 50 BALB/c mice received an application of different cell amounts 
and were then either treated with solvent or dinaciclib (30 mg/kg). 4T1-luc cells were 
subcutaneously injected into BALB/c mice. We used five cell amounts, each amount 
was injected into ten mice. These groups were divided into five mice which received 
either solvent or dinaciclib (30 mg/kg) three times a week. Treatment started on day 
of tumor cell application (d0). Experiment lasted until day 25 (in groups with 1 x 10
6
, 
1 x 10
5 
, 1 x 10
4 
cells) because the bioluminescence signal the imager detected were 
saturated then and mice of these groups were euthanised because of the high tumor 
burden or it ended on day 30 (in groups with 1 x 10
3
 or 1 x 10
2 
cells) after 
application. One mouse in the 1 x 10
5 
cells and vehicle treated group, two mice in the 
1 x 10
5
 cells and dinaciclib treated group and one mouse in the 1 x 10
3
 cells and 
dinaciclib treated group died during the experiment. Figure 45 A shows the tumor 
development over time of ten groups. All mice with 1 x 10
6
 tumor cells injection 
developed almost equal tumors in the control group and the dinaciclib treated group 
over time. On final day of experiment (d25) the control group showed a little higher 
tumor volume than the dinaciclib treated one. In the 1 x 10
5
 and 1x 10
4
 cell amounts 
all mice developed a tumor, in each case the dinaciclib treated group developed the 
higher tumor volume compared to the control. (Figure 45 B)  
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Figure 45: Tumor development over time. A) Shown is the development of tumors of all ten groups 
over time. Mice received either 1 x 10
6
, 1 x 10
5 
, 1 x 10
4
, 1 x 10
3
 or 1 x 10
2
 cells and were either 
treated with dinaciclib or with vehicle. Represented is the mean ± S.E.M. per group. Results are 
statistically evaluated via One-way ANOVA test (n.s.). B) Shown is the tumor volume of each group 
on final day of experiment (day 25 or day 30). Represented is the mean ± S.E.M. per group. Results 
are statistically evaluated via One-way ANOVA test (n.s.). 
 
Bioluminescence imaging with IVIS® Spectrum was performed on day 3, 8, 15, 23 
and 28 after cell application. All mice with the 1 x 10 
6
 and 1 x 10
5
 cell amounts 
developed visible and palpable tumors, the IVIS® imager detected strong 
bioluminescence signals at cell amounts of 1 x 10
6
 and 1 x 10
5
 from day 3 on and 
signals at the cell amount 1 x 10
4
 from day 8 on, but here, one mouse in the control 
group did not develop a tumor at all, no signal was detectable. Mice which received 1 
x 10
3
 cells did not show any visible or palpable tumor during the whole experimental 
period, but in one mouse, treated with dinaciclib, the imager was able to detect a 
bioluminescence signal from day 15 onwards. Mice which received 1 x 10
2 
tumor 
cells did not develop any visible or palpable tumors and the IVIS® was not able to 
detect any bioluminescence signal. (Figure 46) Signals were calculated as total 
flux/area. (Figure 47) 
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Figure 46: Bioluminescence signals of tumor bearing mice.  50 mice were divided into five groups, 
each group received another amount of cells (1.000.000, 100.000, 10.000, 1000, 100, shown in the 
horizontal legend), half of these groups was treated with solvent, the other half with dinaciclib (30 
mg/kg). All mice were imaged with the IVIS® Spectrum in dorsoventral positions, shown is one 
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luminescent image per group. Pictures were generated on day 3, 8, 15, 23 and 28.  Imaging days are 
shown in the vertical legend. 
 
Figure 47: Evaluation of bioluminescence signals. For evaluation regions of interest (ROIs) were 
defined and the total signal per ROI was calculated as photons/second/cm
2
 (total flux/area). All 
signals reached at imaging days (d3, d8, d15, d23) were compared with each other. Represented is the 
mean ± S.E.M. per group. Significance of the results was evaluated using One-way ANOVA test 
(n.s.).  
 
On final days of experiment (day 25 or day 30), mice were euthanised and tumors 
were resected and weighed. Tumor weight was evaluated and results show that in the 
1 x 10
6
 cell amount group, the control group tumors were heavier while in 1 x 10
5
 
and 1 x 10
4
 the dinaciclib treated groups developed heavier tumors. In the 1 x 10
4
 
and 1 x 10
2
 cell amount groups, no tumors were palpable and so no tumors were 
removed. (Figure 48)  
Mice in control group kept a good general condition during the whole experimental 
period. They also gained weight. (49) Mice with dinaciclib treatment showed no 
harmful changes in their body weight, but they showed a reduced general condition 
(horrent fur, isolation from the group, bent position) after dinaciclib injections. 
According to these results, we cannot define any clear statement on effects of an 
Cdk5 inhibition through dinaciclib on reducing the development of 4T1-luc tumors. 
Results are too controversial to draw conclusions.  
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Figure 48: Tumor weight after resection. Shown is tumor weight of mice with 1 x 10
6
, 1 x 10
5
 and 1 
x 10
4
 cells applied. Represented is the mean ± S.E.M. of five mice per group. Significance of the 
results was evaluated using One-way ANOVA test (n.s.).  
 
 
 
Figure 49: Weight of mice over time. Shown is the weight development of 50 mice over time, 
starting with cell application (d0) and euthanasia (d 25 /d30). Weight was assessed six times during 
the experiment. Represented is the mean ± S.E.M. per group. 
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IV. Discussion 
 
 
1. Murine models for preliminary dose finding experiments 
 
One of the first steps in our in vivo experiments was to perform preliminary tests to 
find adequate dose rates which could be used in the main trials. Such experiments 
were realized with the compounds simvastatin, LGR 2674, archazolid A, nutlin-3a, 
PS89 and soraphen A. Mouse strains were chosen according to cell lines which 
should be used for the main experiments, possible accruement of injected cells and 
the duration of tumor growing were the key players in the decision process. All in all, 
simplified setups were used in this kind of experiments, we defined to perform daily 
intraperitoneal injections for all of the compounds in terms of simplification of 
animal handling and stress minimization for the mice.   
Limited numbers of mice per group (n=1 or n=2) were chosen because these 
experiments were just performed to create an informative basis and to provide 
orientation which dosage would be possibly suitable for the main experiments. 
 
Simvastatin is an established inhibitor of cholesterol synthesis, but more and more 
functions become known, among others its anti-cancer activity by activating 
apoptosis [125] [126]. A variety of daily dose rates were already evaluated 
concerning this compound during in vivo experiments by others, orally as well as 
intraperitoneally administered. In our lab we used simvastatin for the first time in a 
murine tumor model. For our HCC models with Huh7 cells the mouse strain of 
choice was Scid, because the human Huh7 tumor cells grow very fast and reliable in 
this B- and T-cell deficient strain. This was the reason why we performed this dose 
finding test exactly with these mice. All animals in the experiment tolerated 10 
mg/kg/d simvastatin in single application and in combination with 0.2. mg/kg/d 
archazolid A well. (Figure 12) 10 mg/kg/d of simvastatin can be categorized as a 
medium dosage, mice would have probably tolerated a higher dose rate but for our 
combinatorial project this medium dosage was optimal. 
 
LGR 2674, an analogue of Cdk inhibitor roscovitine, was evaluated in vivo for the 
very first time. It was compounded within the EU project PROKINASE No. 503467 
and it is claimed to show a higher potency compared to roscovitine [64]. We geared 
our chosen dose rates to the dosage 150 mg/kg/d of roscovitine used in former tumor 
experiments performed in our lab [111]. Concerning the claim to be more effective, 
we decided to evaluate 15 mg/kg/d and 1.5 mg/kg/d for the compound LGR 2674, 
meaning dose rates in ten respectively a hundred times less concentrations. This 
experiment was performed using Scid mice as a suitable strain for Huh7 models. The 
higher dose rate (15 mg/kg/d) turned out to surmount the tolerance level of the mice. 
Using 1.5 mg/kg/d is possible in short time experiments, lasting not longer than a 
few days because mice suffer from weight loss and reduced general condition. 
(Figure 13) Concerning these results the suggestion for further approaches is a clear 
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reduction of the dosage because of the insufficient tolerance of 1.5 mg/kg/d LGR 
2674 over a longer period. 
 
V-ATPase inhibitor archazolid A is a natural compound frequently used in our lab. 
In former in vivo experiments, the authors chose a dosage of 1 mg/kg archazolid A. 
But those mice were treated just twice and the generated results showed no 
significance [127] [31]. Following after these trials, further in vitro and in vivo 
experiments were performed using archazolid A in our group. It emerged more and 
more that mice tolerate only very low concentrations of archazolid A when they were 
daily treated with it. In this thesis, it should be chosen for a long time experiment 
where mice receive a daily injection of the substance over a dozen days. The mice in 
the main trial should get U87MG cells injected, the most suitable strain for these 
cells are BALB/c nu/nu mice. That is why this strain was used in the dose finding 
experiments, too.  So, a variety of dosages were tested, as a basic dosage 0.3 mg/kg/d 
archazolid A was chosen, but this led to deviant results. (Figure 14) Some mice 
tolerated the dosage and some mice did not. This was followed by the decision to 
lower the dosage for long-term trials to 0.2 mg/kg/d as a first step. The dosage of its 
combinatorial agent nutlin-3a was chosen according to Zhang et al. who tested a 
variety of dose rates higher than 5 mg/kg, so we played safe that our chosen dosage 
(5 mg/kg/d) would be tolerated [84]. An explanation for the controversial results 
concerning the 0.3 mg/kg/d archazolid A dosage might be our choice of mouse 
strain. We chose BALB/c nu/nu mice because they should also be used for the main 
experiment, a xenograft model with glioblastoma cells. But this strain is very 
sensible concerning its environment, e.g. temperature and housing conditions, and 
mice of this strain always seemed to be weaker compared to other strains we also 
purchase at an age of five weeks. Within this strain, there exist great discrepancies in 
the weight of single mice compared to each other. So, some mice suffered from a 
general weaker condition. This might be the reason why they were not able to 
tolerate the 0.3 mg/kg/d dosage of archazolid A, however their strain mates in other 
experimental groups tolerated the same dosage well. The consequence for us was to 
use 0.2 mg/kg/d of archazolid A for the mentioned main experiment to make sure all 
mice endure the long lasting trial. For further investigations, other mouse strains 
have to be chosen to evaluate how they tolerate archazolid A in a dose rate higher 
than 0.3 mg/kg/d. 
 
The PDI inhibitor PS89 was evaluated in vivo for the very first time. It was planned 
to use PS89 in a Huh7 tumor model, so Scid mice were chosen for this dose finding 
experiment. Derived from the concentrations which were effective in vitro, we 
decided to evaluate dose rates from 10 mg/kg/d up to 30 mg/kg/d. (Figure 15) All of 
them were tolerated well. With a dosage of 30 mg/kg the limits of solubility were 
almost reached, an unsolved backlog of substance always remained. So, the most 
suitable dosage was 20 mg/kg/d for the usage in a main experiment, not dependent 
on tolerance of the mice but on problems with its solubility. In our case, it was 
IV. Discussion 
 
71 
 
solved in DMSO, solutol and PBS, an approach to increase the possible dosage might 
be to try other solvent combinations. 
 
Very little data exist on the in vivo use of soraphen A until now. Berod et al. 
described the use of soraphen A as a therapeutic agent in inflammatory processes 
[128], but concerning tumor growth and tumor dissemination there exist no data. So, 
we chose soraphen A for a main experiment concerning tumor growth with Huh7 
cells using a Scid mouse strain and a dissemination model with 4T1-luc cells and 
BALB/c mice because they are syngeneic. These strains were used for the 
corresponding dose finding experiments, too. Concentrations were chosen according 
to in vitro data. All concentrations (5 mg/kg/d–20 mg/kg/d) we tested in BALB/c 
mice were tolerated well and we had no solubility problems. (Figure 16 A.) 
Soraphen A should be also used in a xenograft tumor growth experiment with Scid 
mice. The highest dosage tested before lay at 20 mg/kg/d, we tried this one again and 
even doubled the dose rate for Scid mice. But with 40 mg/kg/d as dose rate we were 
almost reaching the limits of solubility little by little. (Figure 16 B) 40 mg/kg/d were 
tolerated and still soluble, so it was chosen for the main experiment. 
This led to the suggestion that soraphen A might be a very tolerable substance for the 
usage in murine tumor experiments, independent from the mouse strain. Limitations 
persist because of solubility problems in concentrations higher than 40 mg/kg. The 
change of  solvent might be an approach for further investigations. 
 
 
2. Murine experiments to evaluate the pharmacokinetics of archazolid A and 
roscovitine 
 
Pharmacokinetic is the umbrella term for all processes in the body which influence 
the applied compound, starting at the resorption, over distribution and metabolisation 
up to elimination [129]. Studies on pharmacokinetics of a substance are a very 
helpful tool to evaluate how long the injected substance stays in the circulation to 
find suitable regimes for the application form and its timed intervals. Namely, results 
strongly depend on the dosage of a substance and its form of application. The aim in 
this chapter was to establish two methods to evaluate the pharmacokinetic behavior 
of V-ATPase inhibitor archazolid A as well as of Cdk inhibitor roscovitine. Both 
substances are frequently used in our lab. 
 
Archazolid A was intraperitoneally as well as intravenously administered, then 30 
min, 1h, 2h, 4h and 6h later blood was taken and the substance concentration in the 
blood at the single points of time were evaluated. In both forms of application the 
concentration of archazolid A lowered after 2h and is almost vanished after 6h which 
led to the suggestion that the half-life of archazolid A is relatively short. (Figure 17 
A) The consequence might be to administer archazolid A at least two times a day. 
The problem is that this substance affects the mice‘ general condition even in low 
dose rates very much, so we made the choice to inject it one time per day. To our 
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knowledge, 0.2 mg/kg/d were tolerated for several days without any bad 
complications. The high blood concentration of archazolid A after i.v. injection 
which surmounts the maximal theoretical value that should be found, can be 
constituted with a PEG impureness in the probes derived from solutol. According to 
Dr. Jennifer Herrmann, who performed the analyses, lay those in the range of the 
used internal standard and disturbed the measurements. A logical consequence for 
future experiments is to spare solutol in the injections and to solve archazolid A just 
in DMSO and PBS, then such an experiment on the pharmacokinetics of archazolid 
A should be repeated. 
  
Roscovitine is an established Cdk inhibitor which is frequently used in tumor 
experiments. A variety of dose rates were used to treat cancer, starting from low 
dosage as e.g. 25 mg/kg [63] up to 150 mg/kg [111] which was used in our 
experiments [130]. Here, we evaluated its blood concentration after i.p. application. 
The concentration reached its peak 30 min after application and held a medium level 
in the blood up to the last measurement (4h). (Figure 18 A) The low value at the 2h 
point of time can be declared as a runaway value, but for future experiments it is 
necessary to choose points of time later than four hours after the application to 
evaluate how the concentration in the blood behaves afterwards. But this preliminary 
result encouraged us for now to adhere to our daily treatment regime because 
roscovitine seemed to reach and hold a plateau level in the blood after i.p. injection. 
But to really confirm this, such an experiment has to be repeated with more points of 
time later than four hours after injection. 
 
 
3. Murine tumor models to evaluate the reduction of tumor growth through 
various compounds 
 
Chemotherapy has been a widely used tool in the fight against cancer for years [131] 
and it is still one method of choice, in human medicine as well as in veterinary 
medicine. Choosing an anti-cancer compound depends on a variety of factors, e.g. 
the type of cancer, potential resistances and the possibility of combinatorial treatment 
regimes [132]. Our lab mainly focuses on natural compounds and their derivatives as 
anti-cancer agents. For this purpose, some of these compounds have been evaluated 
in animal experiments. All cells were injected subcutaneously to form a solid tumor 
whose growth was evaluated under the influence of the experimental anti-cancer 
agents. All experiments were terminated through the general condition of the mice 
and the tumors‘ size. We determined a ceiling of 1000 mm
3
 to exclude illness and 
limitations of physiological behavior and to prevent tumors from necrosis which is 
unflattering for further evaluation on biochemical levels. 
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3.1. Murine tumor models to evaluate the efficacy of archazolid A 
 
The natural compound archazolid A inhibits the so-called V-ATPase which was 
shown to play an important role during cancer processes [133] [29].  In this thesis, it 
was used in three different experiments concerning tumor growth.  
Within a project where the blockade of iron metabolism through the inhibition of V-
ATPases led to therapeutic effects on breast cancer [124], we evaluated the potential 
of V-ATPase inhibitor archazolid A on hampering the growth of murine breast 
cancer tumors (4T1). Archazolid A (1 mg/kg, two times applied) was used in an in 
vivo experiment with BALB/c mice before, these animals also received injections 
with murine breast cancer cells. This experiment led to no clear and significant 
results [31]. That is why we established a totally different experimental setup. 
Therefore, the mouse strain BALB/c nu/nu was chosen and the application regime 
was changed to daily intraperitoneal injections (0.2 mg/kg/d). Therapy of the 4T1 
tumors with archazolid A decreased their volume compared to the control group. 
(Figure 19) This shows that archazolid A has the potential to hamper the growth of 
breast cancer tumors [124]. It might be necessary to vary the experimental setup 
concerning the amount of mice in the groups, we just used n=4. For statistical 
analyses larger groups would be more suitable. Another improvement would be to 
extend the experimental period and to use BALB/c mice for long-term trials because 
they have a firmer general condition and tolerate daily applications better compared 
to the BALB/c nu/nu strain, at least according to our experiences. Furthermore, 4T1 
cells are syngeneic with BALB/c mice where they originate from. 
 
Within a project where the focus lay on the effects of archazolid A on cholesterol 
metabolism, the approach was to evaluate the properties of archazolid A in 
combination with the cholesterol synthesis inhibitor simvastatin (Merck Pharma) 
which is an established therapeutic successfully used in the treatment of high 
cholesterol levels and so reducing the risk for heart attack and stroke [134]. We 
wanted to evaluate with a Huh7 xenograft tumor model if there are any synergistic 
effects within a combinatorial treatment regime of both drugs. The expectation was 
that simvastatin and archazolid A in single therapy would both reduce tumor growth, 
but that the combination of both would reach a greater effect. Archazolid A alone 
hampered tumor growth significantly compared to the control group while the single 
simvastatin treated group showed the highest tumor volume of all groups, even a 
higher one than the control, so the effect of archazolid A in combination with 
simvastatin was worse compared to the single archazolid A treatment, which was a 
controversial result for us. (Figure 21) According to publications, simvastatin might 
promote angiogenesis. Asai et al. showed that systemic treatment with simvastatin 
stimulates wound healing which is impaired in diabetes and constitutes a major 
problem within this disease. Treatment with simvastatin promoted angiogenesis and 
lymphangiogenesis [135]. Furthermore, Fukui et al. showed that a therapy with 
simvastatin after bone fractures promotes neovascularisation and new bone formation 
which accelerates the healing [136]. This might be the explanation why our 
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simvastatin treated tumors reached their large size, instead of promoting the 
inhibitory effect of archazolid A, it stimulated angiogenesis which affected tumor 
growth positively. Especially Huh7 tumors are good vascularized which was even 
increased through simvastatin treatment. So, archazolid A showed its potential to 
hamper tumor growth again, but the combination of archazolid A and simvastatin is 
not suitable for this kind of tumor experiment.  
 
The third in vivo experiment where the potential of archazolid A was evaluated was 
a xenograft model with U87MG (glioblastoma) cells. Glioblastomas belong into the 
group of brain tumors, their prognosis is very poor and almost all patients survive 
less than one year after diagnosis. Glioblastoma is the most malignant primary 
malignant brain tumor in adults. But the overall survival rate enhanced during the 
last decade because the understanding of glioblastomas and therapeutic approaches 
increased. The possibilities to treat them consist of surgery, radiotherapy and the use 
of temozolimide, a cytostatic [137] [138]. So, there is a great need to enlarge the 
therapy of these brain tumors.  
Our lab showed that the inhibition of V-ATPase influences p53 levels positively, so 
we combined archazolid A, a V-ATPase inhibitor with nutlin-3a which was already 
shown to have anti-cancer effects in the fight against glioblastomas before [139], 
because we wanted to evaluate the combinatorial effect of the archazolid A usage 
with an additional p53 activation through nutlin-3a. This experiment showed that the 
growth rate of tumors treated with the combination of archazolid A and nutlin-3a was 
significantly reduced compared to control while the combination also was most 
effective in reducing tumor growth. (Figure 23) This might be a promising 
therapeutic approach against glioblastomas. But these results need further 
investigations, one might be to combine archazolid A with other p53 activators in 
murine tumor models to review if the positive effect is limited to nutlin-3a or if it is 
possible to confer this effect on other combinatorial therapies.  
All in all, archazolid A showed anti-cancer effects in all of the evaluated tumor 
models we performed. 
 
 
3.2. In vivo experiment to evaluate the anti-cancer potential of LGR 2674 
 
HCC is an epithelial liver tumor which is the fifth frequent cancer in the world. It can 
develop from cirrhotic livers due to chronic hepatitis B and C infections or from a 
history of alcohol consumption [105]. The incidence of HCC is rising year by year, 
the prognosis is poor and the only established and admitted therapeutic agent for 
HCC is sorafenib (Bayer Pharmaceuticals) [96] [103]. Our lab already focused on the 
research on HCC treatment within Huh7 cells before [111] and now, in this thesis, 
different approaches to hamper the growth of HCC tumors through the usage of our 
experimental compounds were evaluated in vivo. In all of these experiments Scid 
mice were chosen because human Huh7 cells grow very reliable and fast in this 
mouse strain. 
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The roscovitine analogue LGR 2674 was evaluated in vivo for the first time, it is 
claimed to be more potent than its forerunner concerning the inhibition of Cdk5. 
According to the preliminary dose finding test we performed, 1.5 mg/kg/d were 
chosen as a dosage. LGR 2674 treatment lowered tumor volume significantly 
compared to control. (Figure 25) All mice treated with LGR 2674 lost around 10% 
body weight, showed a reduced general condition and signs of pain after the 
injections, e.g. a bent position, horrent fur and an isolation of single mice from the 
group. All in all, LGR 2674 showed its potential to hamper the growth of Huh7 
tumors and that it seems to be more potent than roscovitine within this setup, because 
roscovitine had to be used in a dosage of 150 mg/kg/d in former experiments to reach 
similar effects. But further experiments are necessary to prove these results. But the 
setup in coming experiments has to be changed, for trials lasting longer than a few 
days, the dosage of LGR 2674 has to be lowered because mice do not tolerate 1.5 
mg/kg over a longer period without retrenchments in their well-being. To evaluate 
the differences between LGR 2674 and roscovitine in detail, both compounds should 
be used within one tumor growth experiment to create equal experimental conditions. 
 
 
3.3. Evaluation of PS89 as anti-cancer agent in a xenograft tumor model 
 
Another approach for HCC therapy was evaluated in a xenograft tumor model. We 
combined the established HCC therapeutic sorafenib with the new PDI inhibitor 
PS89. Sorafenib is an anti-cancer agent that suppresses proliferation and 
angiogenesis of tumor cells through the inhibition of RAF kinase activity and the 
receptors of vascular endothelial growth factor and platelet-derived growth factor. It 
is able to improve the overall survival rate of patients suffering from advanced HCC 
[140]. It is mostly well tolerated and is a viable therapeutic approach, but patients 
with sorafenib treatment lived just three months longer on an average compared to 
placebo groups [141]. So, it is necessary to improve the efficacy of sorafenib and to 
evaluate more potential anti-cancer agents for HCC treatment. So, the combination of 
PS89 and sorafenib was evaluated. But PS89 did not show any sensitizing effect, 
even sorafenib treatment did not lead to any effect on hampering tumor growth.  
(Figure 27) Therefore, we concluded that the explanation lies within the 
experimental setup. Huh7 cells, subcutaneously injected, normally grow very fast 
and form solid tumors around seven days after application at latest. In this setup, the 
tumors grew slower than usual, so we were able to start therapy on day 10 first. 
Within the following days, tumors grew very fast and reached unequal sizes within  
the groups. Besides, mice received therapeutic injections just every second day. The 
combination of the late and then fast growing tumors and the reduced therapy regime 
led to the problem that the anti-cancer agents were not able to work fast and proper 
enough and the huge differences in tumor size within the groups themselves make 
this experiment not comparable with our other HCC trials. So, it is not possible to 
make a statement on the efficacy of PS89 as well as sorafenib. The experimental 
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setup for such an experiment has to be changed. PS89 and sorafenib either have to be 
injected daily when using Huh7 cells or another cell line has to be chosen. 
 
 
3.4. Murine tumor model to evaluate the efficacy of soraphen A 
 
The use of ACC inhibitor soraphen A, a natural compound derived from Sorangium 
Cellulosum is another approach for anti-cancer therapy, although very rare data exist 
concerning its use in vivo. ACCs are major key players in the fatty acid synthesis, 
there exist two isoforms, ACC1 and ACC2, in humans and other mammals. Soraphen 
A is a specific inhibitor of both eukaryotic ACC isozymes [128]. Within one of our 
projects, we evaluated its therapeutic effect by hampering the growth of HCC tumors 
(Huh 7 cells) in Scid mice for the very first time and reached significant results. 
(Figure 28) So, this natural compound showed its potency to act as anti-cancer agent. 
These first results are promising but further experiments are necessary to evaluate 
this data, e.g. the usage of different types of tumor cell lines in combination with 
other mouse strains than Scid. 
 
 
4. In vivo evaluation of new approaches to reduce tumor dissemination 
 
For the in vivo experiments where tumor cell dissemination was the aim to evaluate, 
the bioluminescence imager IVIS® Spectrum was used. For this purpose, murine 
breast cancer cells (4T1) and human leukemia cells (Jurkat) were chosen. To track 
the tumor cell dissemination and the formation of new tumors by using 
bioluminescence imaging, we had to use cells tagged with stable expressing 
luciferase (4T1-luc and Jurkat-luc). When mice carrying 4T1-luc or Jurkat-luc 
tumors and they are injected with luciferin, the tumors emit a visual light signal that 
can be monitored using a sensitive optical imaging system like our IVIS® Spectrum 
[142].  
This kind of bioluminescence imaging contains a variety of advantages within 
murine tumor models. Mice can be imaged several times, so the tumor dissemination 
over time can be reviewed. It can also be used to confirm that i.v. injections were 
performed properly. The imaging procedure itself is not invasive and the isoflurane 
narcosis is harmless and evaporates very fast. But it has to be mentioned that our 
performed experiments represent models for tumor cell dissemination not for tumor 
metastasis itself. Metastasis is defined as a spreading of tumor cells out of a 
cancerous growth into organs away from the original tumor. In our experiments the 
distribution of cells after i.v. injection was reviewed, the cells were injected right into 
the blood circulation, it was no active process as it is in metastatic processes. But 
with our model we were although able to show the main organs which were invaded 
by the injected tumor cells and how long it takes to reach such a tumor cell 
distribution. The dissemination of tumor cells over time was shown without the need 
to sacrifice the mice during the process, which limited the needed number of mice. 
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For a preliminary experiment concerning a leukemia model, we chose Jurkat-luc 
leukemia cells which we were able to get evaluated with the IVIS® Spectrum. As we 
never worked with a leukemia model in vivo before in our lab, the aim was to 
establish a new experimental setup because we wanted to evaluate the general cell 
dissemination after i.v. injection in vivo and to prove which kind of mouse strain is 
suitable for a leukemia model (Scid, Nod-Scid or NSG). 
4T1-luc cells were chosen according to the possibility to track them with the 
bioluminescence imager, their good growth rate and the fact that they can be applied 
into BALB/c mice where they originate from and they are syngeneic with this strain. 
This experimental setup was evaluated before and was successful [127]. All cells 
were injected intravenously to imitate the process of vascular migration, 4T1-luc 
cells migrated from the blood right into the lungs, almost without exception while the 
Jurkat-luc cells invaded a variety of organs.  
 
 
4.1. Establishment of a murine leukemia model 
 
The aim of this experiment was to determine a suitable mouse model for a leukemia 
experiment, here we worked with Jurkat-luc cells. Mice should receive cells via i.v. 
injection, afterwards bioluminescence imaging should be performed to evaluate the 
distribution of the cells in the body. Our future plan was to treat mice, which 
received leukemia cells, with our anti-cancer agents in such models. But because of 
the fact that we used a human leukemia cell line for the first time in one of our in 
vivo experiments, the choice of a suitable mouse strain had to be taken, that is why 
we performed this preliminary experiment. For other leukemia models NSG mice 
were used, but in all of these experiments patient derived leukemia cells have been 
chosen which are very sensible and have special needs for growing [143] [144]. But, 
to our knowledge, there exist no published data on what kind of strain is the most 
suitable for other leukemia cell lines, e.g. Jurkat-luc. So, our aim was to evaluate 
which strain is optimal. Three associated strains which all hold the Scid 
immunodeficiency, Scid, Nod-Scid and Nod Scid Gamma (NSG) mice were chosen. 
The difference between them is that Scid mice hold the Scid deficiency but an intact 
innate immune system while Nod-Scid have additionally a reduced innate immune 
system concerning macrophages, dendritic and natural killer cells and the 
complement system, while NSG mice hold additionally deficits in interleukin 
signaling. Scid and Nod-Scid mice were imaged six times and NSG mice were 
imaged nine times during the experiment. In NSG mice, bioluminescence signals 
were visible from day five after cell inoculation on, the signal increased from day to 
day. However, in Scid and Nod-Scid mice, it was not possible to detect any 
bioluminescence signal over the whole experimental period. Which led to the 
conclusion that probably just NSG mice are suitable for leukemia models, 
independent from the type of injected leukemia cells. (Figure 30) Although all mice 
have similar deficits, it seemed that the interferences in interleukin signaling, which 
just emerge in NSG mice, are decisive for the dissemination of leukemia cells.  
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4.2. In vivo evaluation of the inhibition of tumor cell dissemination by 
tetrandrine and soraphen A 
 
Tumor metastases are the end product of a long cascade of biological steps which 
lead to tumor formation in distinct places far from the original tumor. Metastasis is a 
major problem in therapy because adjuvant therapy or surgical resection can cure 
bounded primary tumors, but concerning metastases it is much more difficult to 
administer a therapy because of its systemic nature and the resistance of 
disseminated tumor cells to existing therapeutic agents. More than 90 % of all deaths 
occurring during cancer disease are attributed to metastasis and not to the primary 
tumors from which these malignant lesions arise [145] [146]. So, it is absolutely 
necessary to search on anti-cancer agents that embank metastasis. Actually, within 
our tumor models, we performed tumor dissemination experiments, because the 
tumor cells did not have to invade actively into the blood circulation, but the new 
tumors which were formed in different organs can be equated with growths arosen of 
a metastatic spread of solid tumors. Our aim was to evaluate the efficacy of two 
natural compounds, Ca
2+
 channel blocker tetrandrine and ACC inhibitor soraphen A, 
against tumor dissemination within different murine models. 
 
For the evaluation of tetrandrine, originally isolated from Stephania tetrandra, 
different allograft experiments with 4T1-luc cells and BALB/c mice were necessary. 
So, our mice and the cells were syngeneic. First, we established a 4T1-luc metastasis 
model where mice were either treated with tetrandrine or vehicle for three times. On 
day eight after cell injection, bioluminescence imaging with the IVIS® Spectrum 
was performed. The tetrandrine treated group showed a higher tumor burden in the 
lungs than the control group. (Figure 32) We actually expected to see the opposite. 
Tetrandrine was solved in DMSO, solutol and PBS in this setup and we had little 
problems to get it solved, so the solution regime had to be adjusted.  
 
We changed the experimental setup then, mice received a combination of tetrandrine 
pre-treated cells and tetrandrine therapy. This time, tetrandrine was solved in sterile 
filtered HCl according to Sakurai et al. [40]. Some of our animals showed small 
wounds at the i.p. injection area referable to the HCl used as solvent. Furthermore, 
the group receiving tetrandrine pre-treated cells in combination with single 
tetrandrine therapy showed the highest tumor burden in the lungs. (Figure 34) So, we 
sought for possible explanations. According to Jin et al., even one i.p. tetrandrine 
application harms the lungs intensely. At a dosage of 150 mg/kg, once applied, 
tetrandrine caused significant alveolar edema and hemorrhage [35]. So, the lungs of 
our mice probably got damaged by tetrandrine itself and so more tumor cells were 
able to form growths there. Treated mice also suffer from a weaker general condition 
compared to control animals. With regard to the wounds after i.p. injections, HCl 
might not be a suitable solvent for tetrandrine. In addition, 4T1-luc cells proliferate 
very fast, with one imaging performance eight days after cell injection, it cannot be 
guaranteed that the amount of tumor cells in the lungs is based on dissemination 
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only. This could also be based on a few cells that migrated into the lungs prior to day 
eight and then proliferated there.  
 
Due to the difficulties of mice treating with tetrandrine, we changed the experimental 
setup completely. Mice received with tetrandrine pre-treated cells compared to mice 
which received control cells. We performed bioluminescence imaging with the 
IVIS® Spectrum two times, on day 5 and day 8 after cell application to provide more 
information on tumor dissemination. On day five, significant results were reached. 
(Figure 36) This shows that tetrandrine has an anti-cancer effect. But its relevance 
for clinical usage when the cells are pre-treated is limited. The better approach surely 
is to administer a therapy in mice. To realize this, a suitable method of application, a 
treatment regime and tolerable solvent have to be evaluated in further experiments, 
lower dose rates of tetrandrine and an improved mixture for its solution are 
absolutely necessary.  
 
A similar experiment was performed with the natural compound soraphen A, 
originally isolated from Sorangium cellulosum. Rare in vivo data exist concerning 
the use of this ACC inhibitor in murine cancer models [147]. We wanted to evaluate 
its effect on tumor dissemination with BALB/c mice syngeneic with 4T1-luc cells. 
Cells were pre-treated with soraphen A in two concentrations and then compared to 
control. (Figure 39) Soraphen A was able to reduce the metastasis of murine breast 
cancer cells in the lungs, which is the main organ they usually invade, in two 
concentrations. But more in vivo experiments with a treatment regime for the mice 
themselves have to be performed to prove the anti-cancer effect in mice and to create 
a transferable conclusion for its use in clinic. We chose this certain setup because a 
former experiment performed by Dr. Rebekka Kubisch (University of Munich, 
Germany) where mice received an i.v. injection of 4T1-luc cells and received 
soraphen A treatment afterwards did not work within such a setup (data not shown). 
All in all, we performed a preliminary in vivo experiment with soraphen A on tumor 
dissemination, but based on the status of available data more investigations are 
deeply necessary.  
 
 
5. In vivo evaluation of the involvement of Cdk5 in cancer processes 
 
Cdk5 is associated with a variety of neuronal diseases because its presence in the 
CNS is incisive [112]. In the last years, its  role in cancer diseases has been evaluated 
more and more. Our lab was already able to show that Cdk5 has a major influence on 
tumor migration and angiogenesis in vitro [117] and in vivo [113] and that an 
inhibition of endothelial Cdk5 leads to reduction of tumor growth [130]. We showed 
that targeting Cdk5 is a new therapeutic approach in HCC treatment [111]. So, we 
wanted to evaluate its potential as a novel target in cancer therapy within our in vivo 
experiments. 
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5.1. Efficacy of Cdk5 knock-down in Huh7 cells and endothelial Cdk5 knock-
out in mice 
 
In cancer research more and more knock-out or knock-down models are used 
nowadays, we contributed to that with a Cdk5 knock-down in Huh7 cells. These 
knock-out cells were injected into mice, which were treated with sorafenib 
afterwards. The chosen dosage of 10 mg/kg i.p. can be classified as a low to medium 
one [100]. It could be shown that the Cdk5 knock-down in cells sensitizes HCC 
tumors to sorafenib treatment in vivo. (Figure 41) This leads to the assumption that 
the inhibition of Cdk5 might be a therapeutical approach to improve the effect of 
sorafenib in HCC therapy, because single sorafenib treatment leads to an average 
longer survival of three months for HCC patients treated with sorafenib than for 
those given placebo [96]. But not all patients are sensible for sorafenib treatment 
because of resistances [148]. So the combination of sorafenib treatment with Cdk5 
inhibition might be a promising therapeutic improvement, but more investigations 
are necessary. Especially for clinical use, there have to be more experiments 
concerning a Cdk5 inhibition through a chemotherapeutic that can be systemically 
administered. 
 
Concerning a project where the influence of endothelial Cdk5 in tumor angiogenesis 
was evaluated, we performed an in vivo experiment with mice carrying an inducible 
endothelial Cdk5 knock-out (Cdk5 
fl/fl
 VECCre+). Mice were generated by using a 
Cre-lox system, here the endothelial Cdk5 knock-out was inducible through 
tamoxifen treatment. A general Cdk5 knock-out in mice is not possible because such 
animals are nonviable. Murine melanoma cells were injected, and when our mice 
beared a tumor, they were either treated with Cdk inhibitor roscovitine or vehicle, the 
first ones showed a lower tumor volume in the end of the experiment. (Figure 42) 
We were able to show that an inducible endothelial Cdk5 knock-out in mice 
sensitized tumor cells for chemotherapeutic treatment [130]. Due to limitations in 
animal breeding, our number of Cdk5 knock-out mice in the groups was relatively 
small (n=3). It would be an improvement to enlarge the experimental groups to lower 
the deviations between the single tumor volumes. 
  
 
5.2. Evaluation of the effect of Cdk5 inhibition in murine limiting dilution 
experiments 
 
Solid tumors consist of heterogeneous populations of cancer cells which have 
different abilities to proliferate and to form metastasis. Some cancer cells have 
limited properties to divide, while others, so-called tumor initiating cells have been 
identified to possibly have the ability to extensively proliferate and form new tumors 
[149]. Our aim was to evaluate which effect the number of injected tumor cells (4T1-
luc and T24) has on tumor development and growth, both in combination with a form 
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of Cdk5 inhibition. The background of these experiments was to evaluate the tumor 
initiating potential of CSCs in different cell lines. 
We evaluated a xenograft tumor model with human urinary bladder cancer cells 
(T24) which contained a stable Cdk5 knock-down (T24 Cdk5 shRNA) and compared 
their start of growing and development with control cells (T24 nt shRNA). As a 
result, we are not able to make any clear suggestions. T24 nt shRNA tumors as well 
as T24 Cdk5 shRNA tumors were visible and palpable from the same time points on. 
(Figure 43) The expectation was that Cdk5 knock-down in tumor cells would 
influence the time of tumor arising and growth negatively compared to the control 
cells without Cdk5 knock-down. Further investigations on biochemical levels were 
renounced because of the misleading results. But a cell amount of 1 x 10
6
 seemed to 
lay the best foundations for tumor formation. So, it might not depend on how much 
tumor cells are injected, because 5 x 10
6
 and 2.5 x 10
6
 cells led to a lower tumor 
volume in general. If such an experiment has to be repeated, the experimental setup 
has to be totally changed.  
 
The second limiting dilution experiment we performed is based on an allograft tumor 
model with murine breast cancer cells and BALB/c mice, hence a syngeneic model. 
Two groups of mice (n=5) always received the same cell amount. One of those 
groups was treated as a control the other received the Cdk5 inhibitor dinaciclib. 
Bioluminescence imaging was used to evaluate tumor metastasis within the body. 
Results exhibited a great variety of information, a suggestion which tumors arise first 
or reach the higher volume cannot be made. (Figure 45) The value of this experiment 
cannot be enlarged through bioluminescence images. (Figure 46) We actually 
expected that tumor volume should be hampered by dinaciclib treatment. An 
explanation for the controversial results might be that mice with dinaciclib treatment 
suffered from a worse general condition than the control mice did after the injection 
and so, their immune system was harmed through dinaciclib treatment so much that 
tumor cells had a better chance to invade the lungs and proliferate there before 
dinaciclib was able to attend its function as chemotherapeutic. If such an experiment 
should be repeated, it might be an improvement to lower the dosage of dinaciclib and 
to choose a cell line which proliferates slower than 4T1-luc cells. 
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V. Summary 
 
 
Cancer diseases are a major burden on human and animal health, their number will 
even increase in the coming years, according to statistics. The current strategies of 
therapy do often not suffice to cure patients or to enhance their survival rate at least. 
Negative therapeutic side effects, resistances and the formation of metastasis are 
unfortunately huge stumbling blocks in cancer therapy. So, there is a great need for 
improved or new therapeutics. Therefore, our lab focuses on new cytostatic drugs, 
originated from natural compounds or their derivatives for anti-cancer treatment. The 
aim of this thesis was to establish murine tumor models to evaluate the anti-cancer 
potential of these compounds in vivo. We performed different animal experiments to 
review their effects on hampering tumor development, growth and dissemination. 
Partly, the focus was laid on cyclin-dependent kinase 5 (Cdk5) as a target for cancer 
therapy. Many of the current projects in our lab are about the use of such compounds 
and a variety of in vitro data were already collected. This thesis contributes to these 
projects with the establishment and realisation of corresponding in vivo experiments 
to reach profound knowledge on the efficacy of the experimental drugs. 
Natural compounds and their derivatives are a great source for anti-cancer agents and 
have broad therapeutic effects, furthermore they are often the template for synthetical 
drugs. So, their use in the fight against cancer is auspicious and indispensable. 
For their evaluation, we started with the performance of some dose finding and 
pharmacokinetic experiments. Afterwards we evaluated the influence of different 
anti-cancer drugs on tumor growth and tumor dissemination. A variety of different in 
vivo experiments was established and we were able to show within these chosen 
setups that V-ATPase inhibitor archazolid A is able to hamper the growth of breast 
cancer tumors, hepatocellular carcinomas and glioblastomas, partly in combination 
with other drugs. For example, its combination with MDM2 inhibitor nutlin-3a 
reached synergistic effects against cancer cells, while the usage of cholesterol 
synthesis inhibitor simvastatin together with archazolid A was not promising. 
Archazolid A demonstrated in all of our experiments its potential as a cytostatic. But 
further investigations are needed to evaluate its efficacy in more complex 
experiments.  
The natural compound tetrandrine, a Ca
2+
 channel inhibitor, was shown to reduce 
tumor metastasis of breast cancer cells in an allograft mouse model while the natural 
compound soraphen A, an ACC inhibitor, showed promising results in hampering 
tumor growth of hepatocellular carcinoma cells as well as the dissemination of breast 
cancer cells, evaluated in xenograft and allograft tumor models. 
All natural compounds we investigated showed potential as anti-cancer agents. 
Next to these drugs, we also investigated the efficacy of some new synthetic 
chemotherapeutics.  
PDI inhibitor PS89 was chosen to sensitize hepatocellular carcinoma tumor cells for 
treatment with the established HCC therapeutic sorafenib, but with the chosen 
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experimental setup we were not able to evaluate its potential, so PS89 should be 
chosen for further experiments. 
Within a xenograft tumor model we were able to demonstrate that LGR 2674, an 
analogue of Cdk inhibitor roscovitine, hampered the growth of hepatocellular 
carcinomas. This substance was used in this kind of experiment for the first time, so 
we used simplified setups and further in vivo examinations are to be pursued.  
A special mechanism in the fight against cancer is the inhibition of Cdk5, which was 
already shown to be involved in the development and progression of cancer. 
According to this, we realised different in vivo experiments where we focused on 
Cdk5 as a target. Hepatocellular carcinoma cells carrying a stable Cdk5 knock-down 
were compared to control cells, with and without sorafenib treatment and so we were 
able to demonstrate in a xenograft mouse model that a Cdk5 knock-down in cells 
sensitizes tumor cells for sorafenib treatment. This might be a good therapeutic 
innovation concerning existing resistances against sorafenib. In another experiment 
mice with an inducible endothelial Cdk5 knock-out were used and treated with the 
Cdk inhibitor roscovitine which led to a sensitizing effect on tumor cells for therapy. 
All in all, we were able to establish murine tumor models to demonstrate that Cdk5 is 
a promising target in cancer therapy. 
In addition, two murine limiting dilution experiments were performed to evaluate the 
influence of cancer stem cells on tumor development and growth, in both 
experiments a Cdk5 inhibition was additionally used. One experiment with human 
urinary bladder cancer cells containing a Cdk5 knock-down  and another experiment 
where Cdk5 was inhibited through dinaciclib led both to no evaluable results. The 
experimental setup for such experiments has to be changed. 
In conclusion, this thesis deals with the realisation of murine tumor models for the in 
vivo evaluation of new therapeutic approaches in cancer therapy, based on natural 
compounds and their derivatives. Cdk5 was partly focused as an anti-cancer target. 
Many of the presented results are promising and display encouraging possibilities for 
cancer therapy, they are initial points for further in vivo investigations. 
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VI. Zusammenfassung 
 
Murine Tumormodelle für die in vivo Evaluierung von Naturstoffen und ihren 
Derivaten als neue Krebstherapeutika 
 
 
Krebserkrankungen stellen eine große Belastung für die menschliche und tierische 
Gesundheit dar, ihr Auftreten soll Statistiken zufolge in den nächsten Jahren sogar 
noch ansteigen. Die gängigen Behandlungsstrategien reichen oftmals nicht aus um 
die Patienten zu heilen oder zumindest ihre Überlebensdauer zu verbessern. 
Therapeutische Nebenwirkungen, Resistenzen und die Bildung von Metastasen sind 
leider große Stolpersteine innerhalb der Krebstherapie. Somit besteht ein großer 
Bedarf für verbesserte oder neue Therapien. Dementsprechend fokussiert sich unser 
Labor auf neue Zytostatika, die von Naturstoffen oder deren Derivaten abstammen 
und für die Krebstherapie eingesetzt werden können. Das Ziel dieser Arbeit war es 
Tumormausmodelle zu etablieren um das Potential dieser Stoffe in vivo zu 
untersuchen. Wir haben verschiedene Tierexperimente durchgeführt um deren 
Einfluss auf Tumorentstehung, Wachstum und Dissemination zu untersuchen. 
Teilweise wurde der Fokus dabei auf die cyclinabhängige Kinase 5 (Cdk5) als Target 
in der Krebstherapie gelegt. Viele unserer aktuellen Projekte beschäftigen sich mit 
dem Einsatz solcher Substanzen und verschiedenste in vitro Daten wurden bereits 
generiert. Diese Arbeit leistet mit der Etablierung und Realisierung von den 
dazugehörigen tierexperimentellen Versuchen einen Beitrag zu all diesen Projekten, 
um ein grundlegendes Wissen über die Effizienz der Versuchssubstanzen erlangen zu 
können. 
Naturstoffe und ihre Derivate stellen eine große Quelle für Substanzen dar, die gegen 
Krebs eingesetzt werden konnen und weisen breite therapeutische Effekte auf, 
darüberhinaus dienen sie häufig als Grundlage zur Herstellung synthetischer 
Medikamente. Dementsprechend ist ihr Einsatz in der Krebstherapie 
vielversprechend und unabdingbar. 
Um diese Stoffe zu untersuchen haben wir damit begonnen einige tierexperimentelle 
Versuche zur Dosierungsbestimmung und zur Pharmakokinetik durchzuführen, im 
Anschluss haben wir den Einfluss von verschiedensten Stoffen auf Krebszellen im 
Hinblick auf Tumorwachstum und Tumordissemination hin überprüft.  
Eine Reihe verschiedenster in vivo Experimente wurde etabliert, so konnten wir mit 
den gewählten Versuchen zeigen, dass der V-ATPase Hemmer Archazolid A das 
Wachstum von Brustkrebstumoren, hepatozellulären Karzinomen und Glioblastomen 
verringern kann, teils auch in Kombination mit weiteren Substanzen. Beispielsweise 
hat eine Kombination mit dem MDM2 Hemmer Nutlin-3a synergistische Effekte 
gegen die Krebszellen gezeigt, während eine Kombination mit dem 
Cholesterolsynthesehemmer Simvastatin zu keinen befriedigenden Ergebnissen 
geführt hat. Archazolid A selbst hat in all unseren Versuchen sein Potential als 
Zytostatikum unter Beweis gestellt. Es sollte nun in weiteren Experimenten 
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eingesetzt werden, damit seine Wirksamkeit in komplexeren Versuchen überprüft 
werden kann. 
Es konnte außerdem gezeigt werden, dass der Naturstoff Tetrandrin, ein 
Calciumkanalhemmer, die Dissemination von Brustkrebszellen reduzieren kann, 
während der Naturstoff Soraphen A, ein ACC Hemmer, vielversprechende Effekte 
bei der Hemmung des Tumorwachstums von hepatozellulären Karzinomen und der 
Dissemination von Brutskrebstumoren in einem xenograften bzw. einem allograften 
Tumormodell gezeigt hat. 
Alle Naturstoffe, die wir untersucht haben, haben ihr Potential für den Einsatz in der 
Krebstherapie unter Beweis gestellt. Neben diesen Naturstoffen, haben wir aber auch 
das Potential von einigen neuen synthetischen Chemotherapeutika untersucht. 
Der PDI Hemmer PS89 sollte hepatozelluläre Karzinomzellen für die Therapie mit 
dem etablierten HCC Medikament Sorafenib sensibilisieren, mit dem gewählten 
Versuchsaufbau war es uns aber nicht möglich die Effekte von PS89 auszuwerten, 
dementsprechend sollte PS89 in weiteren Experimenten zum Einsatz kommen. 
Mit einem xenograften Tumormodell konnten wir zeigen, dass LGR 2674, ein 
Analog des Cdk Hemmers Roscovitin, das Wachstum von hepatozellulären 
Karzinomen verringern kann. Diese Substanz wurde zum allerersten Mal in solch 
einem Versuch eingesetzt, dementsprechend wurden vereinfachte 
Versuchbedingungen gewählt, somit sind weitere tierexperimentelle Versuche 
anzustreben. 
Ein spezieller Mechanismus in der Krebstherapie ist die Hemmung der 
cyclinabhängigen Kinase 5, von der bereits gezeigt wurde, dass sie in 
Tumorentstehungs- und Fortschreitungsprozesse involviert ist. Dementsprechend 
haben wir verschiedene in vivo Versuche durchgeführt, in denen der Fokus auf Cdk5 
als Target gelegt wurde. Hepatozelluläre Karzinomzellen, die einen stabilen Cdk5 
Knock-down trugen wurden mit Kontrollzellen verglichen, entweder mit oder ohne 
anschließender Sorafenib Behandlung. Wir konnten in einem xenograften 
Mausmodell zeigen, dass ein Knock-down von Cdk5 die Zellen für die Sorafenib 
Therapie sensibilisiert, was einen neuen vielversprechenden Ansatzpunkt im Bezug 
auf bestehende Resistenzen gegen Sorafenib darstellt. In einem weiteren Experiment 
wurden Mäuse, die einen induzierbaren endothelialen Cdk5 Knock-out trugen mit 
dem Cdk Hemmer Roscovitin behandelt, was dazu führte, dass die Tumorzellen für 
die Therapie sensibilisiert wurden.  
Zusammengefasst war es uns möglich Tumormausmodelle zu etablieren mit denen 
wir zeigen konnten, dass Cdk5 ein vielversprechendes Target in der Krebsforschung 
darstellt. 
Zusätzlich haben wir zwei tierexperimentelle Limiting Dilution Versuche 
durchgeführt um den Einfluss von Krebsstammzellen auf die Tumorentstehung und 
das Tumorwachstum zu untersuchen, in beiden Experimenten wurde zusätzlich eine 
Cdk5 Hemmung induziert. Sowohl ein Versuch mit menschlichen Blasenkrebszellen, 
die einen Cdk5 Knock-down trugen als auch ein Versuch in dem Cdk5 durch 
Dinaciclib gehemmt wurde, führten zu keinen auswertbaren Ergebnissen. Das 
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experimentelle Vorgehen für derartige Versuche muss grundlegend verändert 
werden. 
Zusammenfassend handelt diese Arbeit von der Realisierung von murinen 
Tumormodellen für die in vivo Evaluierung neuer therapeutischer Ansätze in der 
Krebstherapie, basierend auf Naturstoffen und ihren Derivaten. Teilweise wurde der 
Fokus dabei auf Cdk5 gelegt. Viele der Ergebnisse sind aussichtsreich und stellen 
vielversprechende Möglichkeiten für die Krebstherapie dar, diese können als 
Ausgangspunkt für weitere tierexperimentelle Untersuchungen angesehen werden.
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1. Abbreviations 
 
°C   degree Celsius 
ACC   acetyl-CoA-carboxylase 
ATP   adenosine triphosphate 
BC   biotin carboxylase 
BCCP   biotin carboxyl carrier protein 
BCS   body condition score 
BMEL   Bundesministerium für Ernährung und Landwirtschaft 
Ca
2+
   calcium 
Cdk5   cyclin dependent kinase 5 
CH3   methyl group 
CNS   central nervous system 
CO2   carbon dioxide 
CoA   coenzyme A 
CLL   chronic lymphocytic leukemia 
CSC   cancer stem cell 
CT   carboxytransferase 
d   day(s) 
DMSO  dimethyl sulfoxide 
Dr.   doctor (PhD) 
DFG   Deutsche Forschungsgemeinschaft 
EDTA   ethylendiaminetetraacetate 
e.g.   exempli gratia (for example) 
EMT   epithelial mesenchymal transition 
ER   endoplasmatic reticulum 
FCS   fetal calf serum 
FELASA  Federation of European laboratory animal science associations 
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G   Gauge 
H   height 
h   hour(s) 
H+   hydrogen 
HCC   hepatocellular carcinoma 
HCl   hydrochloric acid 
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A 
HPLC   high performance liquid chromatography 
i.p.   intraperitoneal(ly) 
i.v.   intravenous(ly) 
IVC   individual ventilated cage 
IVIS®   in vivo imaging systems 
K   potassium 
kg   kilogram 
KH2PO4  kaliumhydrogenphosphate 
L   length 
LD50   median lethal dose 
LDL   low density lipoprotein 
LOEL   lowest observed effect level 
luc   luciferase 
MDM2  mouse double minutes clone 2 
mg   milligram 
min   minute(s) 
ml   milliliter 
n   number(s) 
Na2HPO4  dinatriumhydrogenphosphate 
NAADP  nicotinic acid adenine dinucleotide phosphate 
NaCl   sodium chloride 
No.   number 
NOEL   no observed effect level 
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n.s.   not significant 
NSG   Nod Scid Gamma 
nt   non targeting 
O2   oxygen  
PBS   phosphate buffered saline 
PDI   protein disulfide isomerase 
PEG   polyethylene glycols 
PFA   paraformaldehyde 
Prof.   Professor 
R   rest 
RNA   ribonucleic acid 
ROI   region of interest 
rpm   rounds per minute 
s.c.   subcutaneous(ly) 
Scid   severe combined immunodeficiency   
S.D.   standard deviation 
sec   second(s) 
S.E.M.   standard error of the mean 
shRNA  small hairpin ribonucleic acid 
TE   trypsin EDTA solution 
TD50   median toxic dose 
TPC   two-pore channel 
UPR   unfolded protein response 
UV   ultraviolet 
V-ATPase  vacuolar-type H+ ATPase 
W   width 
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